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ABSTRACT
S. aureus is the dominant cause of skin and soft tissue infections (SSTIs) in
humans. The importance of S. aureus as the primary cause of skin infections has
increased exponentially over the last few decades since the emergence of resistance
to β-lactam antibiotics. Furthermore, the rise of methicillin-resistant S. aureus
(MRSA) strains has led to hospitals stays, increased financial burden and increased
mortality. A significant proportion of MRSA infections have been attributed to
community-acquired strains (CA-MRSA), specifically the USA300 isolates, which
can cause deadly disease in otherwise healthy individuals. Due to the increase in
antibiotic resistance and the lack of an effective vaccine against S. aureus, there is a
limit in current treatment options available for infected patients and a need for
better therapeutics that limit resistance while fighting infection. In order to design
better therapeutics to combat S. aureus, it is imperative to understand the host
innate immune factors that are protective against S. aureus. Our work focuses on
the role of the scavenger receptor CD36 in regulation of the host inflammatory
response during S. aureus skin infection, sex bias in susceptibility to infection with
S. aureus, and the role of estrogen in host defense during infection. This work is
especially important for patient populations which show increased susceptibility to
infection due to dysfunctional innate immune mechanisms.
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Chapter 1 Introduction
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This introduction chapter is divided into four parts. Part 1 will discuss the
discovery, isolation and epidemiology of the bacterial pathogen Staphylococcus aureus,
as well as current treatment options. Additionally, this section will focus on virulence
factors used by S. aureus to cause infections, how the skin functions as a general barrier
against infection and how the host immune system functions to combat skin infections
caused by S. aureus. Part 2 will discuss the known functional roles of the scavenger
receptor cluster of differentiation 36 (CD36), including roles of this receptor in the host
immune response to S. aureus infection. Part 3 will focus on epidemiological data and in
vitro and in vivo studies supporting a sex bias in susceptibility to bacterial infections, as
well as providing an overview of the cellular response to estrogen signaling. Part 4
contains concluding remarks and hypothesis for the work in this dissertation.
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Part 1: Combatting the bacterial pathogen Staphylococcus aureus

Discovery and isolation of S. aureus
The Staphylococcus genus is composed of at least 40 different species of bacteria,
many of which impact human health. Staphylococcus was first isolated in 1880 by the
Scottish surgeon Alexander Ogston from the abscess of a patient (Ogston, 1881). He
lanced the abscess and smeared the pus onto a microscope slide for analysis and observed
the presence of clusters of bacteria within the pus debris, which he termed
“staphylococci” from the Greek word staphyle referring to bunches of grapes. Ogston
then experimented by injecting pus from his human patients into the skin of mice and
observed the development of an abscess (Ogston, 1882). When he heat-treated the pus
samples, the mice did not develop an abscess, indicating to Ogston that acute abscesses
were caused by a bacterial source and demonstrating the importance of aseptic practices
during surgical operations to prevent post-operative mortality. A few years later, in 1884,
the German surgeon Anton Rosenbach, isolated two different strains of staphylococci,
which he named based on the colonies’ pigmented appearance, Staphylococcus aureus
for the Latin word aurum for “gold” and Staphylococcus albus for the Latin word albus
or “white” (now referred to as S. epidermidis) (Rosenbach, 1884). Since its isolation, it
has been shown that S. aureus is responsible for a wide range of infections in humans
including osteomyelitis, endocarditis, pneumonia, bacteremia, and skin infections
(Lowry, 1998). Despite its identification over 100 years ago, S. aureus is still regarded as
a serious public health threat to humans.
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Epidemiology of S. aureus infections
S. aureus is the dominant cause of skin and soft tissue infections (SSTIs) (Moran
GJ and LK, 2006). S. aureus SSTIs in the USA account for 11.6 million outpatient and
emergency room visits, as well as 500,000 hospital admissions per year (McCaig et al.,
2006). The importance of S. aureus as the primary cause of skin infections has increased
exponentially over the last few decades since the emergence of resistance to β-lactam
antibiotics, such as penicillin and ampicillin. Resistance to these antibiotics is due to the
acquisition of blaZ, which is translated into the β-lactamase enzyme that hydrolyzes the
β-lactam ring rendering the antibiotic inactive (Lowry, 2003). In 1961, the antistaphylococcal antibiotic methicillin was introduced as an antibiotic resistant to the
effects of β-lactamase. Shortly after the introduction of methicillin, methicillin-resistant
S. aureus (MRSA) isolates were reported (Lowry, 2003). MRSA antibiotic resistance is
due to the acquisition of the chromosomally-inserted staphylococcal cassette
chromosome mec (SCCmec), which contains the mecA gene, that codes for penicillinbinding protein 2a (PBP2a). Penicillin binding proteins (PBPs) catalyze transpeptidation
for peptidoglycan cross-linking during bacterial cell wall formation, and are the target of
β-lactam antibiotics. PBP2a is structurally unique, thereby conferring resistance to not
only the anti-staphylococcal β-lactam antibiotics, methicillin, nafcillin, and oxacillin, but
also to all penicillins, carbapenems, and most generations of the cephalosporins
(Chambers and Deleo, 2009).

In a recent report, 76% of bacterial skin infections

presenting to the emergency room were due to S. aureus infection, and of those, 78%
were caused by MRSA (Moran GJ and LK, 2006).

Compared to infections caused by

methicillin-sensitive S. aureus (MSSA), MRSA infections are associated with increased
4

mortality rates, longer hospitals stays and increased financial burden (Lodise and
McKinnon, 2007). Even more concerning, a significant proportion of MRSA infections
are due to community-acquired strains (CA-MRSA), specifically isolates of the pulsedfield gel electrophoresis (PFGE) type USA300, which can cause deadly disease in
otherwise healthy individuals (Otto, 2013).

In addition, MRSA has been labeled a

serious threat by the CDC (CDC, 2013). From this epidemiological data, it is clear that S.
aureus is a deadly pathogen responsible for a major burden on the health care system.
Current treatment regimens for S. aureus skin infections are dictated by the type
and severity of infection.

Skin infections can be categorized as uncomplicated or

complicated (U.S.DHHS, 1998).

Uncomplicated skin infections include impetigo

(superficial sores), folliculitis (inflammation of hair follicles) and infected abrasions, and
are often treated with incision and drainage in an outpatient setting (Rajan, 2012;
Schmitz, 2011). Complicated skin infections include major abscesses, infected burns,
and deep tissue infection called necrotizing fasciitis. These infections often require
hospitalization, wound debridement via surgery, and antibiotics (Dryden, 2010; May,
2011).

Gram stain and culture of pus or exudate is recommended for pathogen

identification, along with susceptibility testing to identify the best method of antibiotic
treatment. To treat moderate MSSA infections, patients are prescribed dicloxacillin or
cephalexin, and for more severe MSSA infections nafcillin or clindamycin is prescribed
(Stevens et al., 2014).

To treat MRSA infections, patients may be prescribed

trimethoprim/sulfamethoxazole, linezolid or ceftaroline (Stevens et al., 2014). Since
there is now a limit in current treatment options as antibiotic resistance grows, and no
protective vaccine exists, it is imperative to better understand not only the virulence
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factors that S. aureus uses to cause invasive infection, but also how the immune system
combats S. aureus skin infection.

This knowledge could facilitate the design of

therapeutics to bolster the immune system’s ability to fight S. aureus infection (DeLeo et
al., 2010).

Virulence Factors Arsenal of S. aureus
S. aureus is a human commensal of the skin and it is estimated that at least 30% of
the human population is colonized with S. aureus, and up to 60% of the population is
transiently colonized (Klevens et al., 2007). Humans are most often colonized by S.
aureus within the nares or inguinal region of the body (Yang et al., 2010). S. aureus has
an arsenal of factors that enable it to successfully colonize humans and to breach the
innate skin barrier (described below). It is important to understand the mechanisms of
colonization because colonization is a risk factor for subsequent S. aureus infection
(Kluytmans et al., 1997). The factors that promote colonization include S. aureus surface
components that increase adherence to host cell surfaces. These colonization factors are
called microbial surface components recognizing adhesive matrix molecules, or
MSCRAMMs, and include fibronectin-binding protein A and B (FnbpA, Fnbp B),
clumping factor A and B (ClfA, ClfB), iron-regulated surface determinant A (IsdA) and
wall teichoic acid (WTA) (Krishna and Miller, 2012a). FnbpA and Fnbp B are adhesins
that function to create a bridge between the host cell membranes and S. aureus via
fibronectin in the extracellular matrix (Cho et al., 2001). ClfA, ClfB and IsdA enable S.
aureus to adhere to fibrinogen, a glycoprotein converted into fibrin during blood clot
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formation. These proteins guide bacterial clumping to prevent phagocytosis by host
immune cells (Corrigan et al., 2009). WTA is a surface exposed polymer covalently
attached to peptidoglycan and has been known to be integral for S. aureus adherence to
human epithelial cells (Weidenmaier et al., 2004).

In the event of successful

colonization, the risk of S. aureus switching from a colonization phenotype to an invasive
phenotype increases.
Like many bacteria, S. aureus expresses different proteins at different stages of
growth and in different niches, including during the switch from a colonizing to an
invading phenotype.

It is essential to understand how S. aureus switches from

colonization to invasion, in order to design better treatment options that target these
distinct phenotypes. Quorum sensing is a density-dependent sensing mechanism used by
many pathogens to globally regulate the appropriate response to changing environmental
conditions (Rutherford and Bassler, 2012). Quorum sensing in S. aureus regulates the
phenotype switch from colonizing commensal to invasive pathogen using the accessory
gene regulator (agr), which is a four gene operon consisting of agrA-D (Figure 1.1)
(Novick and Geisinger, 2008; Parker and Sperandio, 2009). The components of this
operon encode the linear peptide AgrD, the transmembrane protein AgrB, the receptor
histidine kinase AgrC and the intracellular response regulator AgrA. AgrB is responsible
for the processing of AgrD into a cyclized auto-inducing peptide (AIP), as well as
exporting it into the extracellular space. Secreted AIP binds its cognate receptor, AgrC,
which phosphorylates and activates AgrA that acts as a transcription factor to promote
transcription from two divergent promoters, P2 and P3 (Novick and Geisinger, 2008;
Thoendel et al., 2011). Activation of the P2 promoter drives transcription of the agr
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operon in a positive feed-forward signal, while activation of the P3 promoter leads to
RNAIII production (Painter et al., 2014). RNAIII in turn regulates expression of over
200 virulence factors (Novick, 2003; Queck et al., 2008). Understandably, the agr
operon is often studied for its contribution to infection and disease.

Figure 1.1 S. aureus accessory gene regulator (agr) operon.
The agr P2 promoter drives expression of the genes encoding the four proteins required
for agr signaling. AgrD is the linear precursor of the agr auto-inducting peptide (AIP).
AgrB secretes AIP from the bacteria where it binds to its cognate receptor, AgrC, on the
bacterial membrane, which leads to phosphorylation of AgrA and activation of the P2 and
P3 promoters. P3 promoter activation generates RNAIII which regulates expression of
virulence factors which drive invasive infection. Adapted from (Novick and Geisinger,
2008).
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Some of the virulence factors regulated by the agr operon that are important for
invasive skin infections include alpha-hemolysin and the phenol soluble modulins. Alpha
hemolysin (Hla) is one of the major virulence factors responsible for dermonecrosis
during skin infection (Kennedy et al., 2010), and its production is, in large part, posttranscriptionally regulated by RNAIII under the agr operon (Xiong et al., 2006). Hla is
secreted as a monomer and binds disintegrin and metalloprotease 10 (ADAM-10) on host
cells. ADAM-10 is localized to the cell membrane and its functional role is to cleave Ecadherin to untether the adherens junctions between adjacent epithelial cells (Maretzky et
al., 2005).

ADAM10 provides a docking site for a monomer of Hla, which then

oligomerizes to form a pore within the host cell membrane (Wilke and Bubeck
Wardenburg, 2010). Pore formation leads to loss of intracellular potassium from the host
cell, eventually leading to cell death (Walev et al., 1993). In addition, upon Hla binding,
ADAM-10 relocalizes to lipid rafts enriched in caveolin. (Wilke and Bubeck
Wardenburg, 2010).

ADAM-10 and Hla complex formation leads to disruption of

endothelial cell-cell focal adhesion to perturb cellular barriers for more invasive disease
(Hocke et al., 2006; Wilke and Bubeck Wardenburg, 2010), such as providing a gateway
for S. aureus superantigens to pass the host mucosal membrane (Brosnahan et al., 2009).
Despite knowing that infection with Hla-expressing S. aureus leads to severe damage to
the epidermis and dermis of the skin (Kennedy et al., 2010), it has not been thoroughly
investigated as to how the host immune system regulates the subsequent inflammation
and limits the damage caused by both Hla and the immune response to Hla.
Phenol soluble modulin (PSM) expression is regulated by the agr operon and has
also been shown to be a major determinant of S. aureus virulence (Wang et al., 2007a).
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PSMs are amphipathic peptides of which there are 7 types classified into two groups
based on their length. The α-type PSMs (PSM α1-PSM α4) are half the size of the β-type
PSMs (PSMβ1-PSMβ2, and δ toxin) (Cheung et al., 2014). PSMs have been shown to
contribute significantly to S. aureus skin infection (Kobayashi et al., 2011a; Wang et al.,
2007a). Furthermore, it was recently demonstrated that psmα expression modulates
production of Hla, suggesting that coordinated action of the two toxins is necessary to
achieve epithelial injury during S. aureus infections (Bryan J. Berube et al., 2014).

The Skin as a Barrier to S. aureus Infection
The surface of the skin is the first layer of defense against infection by potentially
pathogenic bacteria. The skin surface is not hospitable to many types of bacteria due to its
low temperature of 32-34°C, acidic pH, secreted antimicrobial peptides, and other
resident commensals (Krishna and Miller, 2012b). The low pH of the skin is due to the
breakdown of filaggrin, which binds keratin fibers in epithelial cells during keratinocyte
differentiation. This leads to production of pyrrolidone carboxylic acid and urocanic
acid, which have been shown to directly inhibit the growth of S. aureus (Miajlovic H,
2012).

Another barrier to skin colonization includes the large class of antimicrobial

peptides that are secreted by keratinocytes in the human epidermis, including β-defensins
(hBD2, hBD3) and cathelicidin (LL-37) (Krishna and Miller, 2012a; Peschel and Sahl,
2006). In the murine epidermis, cathelicidin-related AMP (CRAMP), a homolog of LL37, and mouse β-defensin 4 (mBD4), an ortholog of hBD2 are expressed (Bauer and
Shafer, 2015). β-defensins are cationic and as such can interact with the negatively

10

charged membrane components lipoteichoic acid (LTA) for Gram positive bacteria and
lipopolysaccharides (LPS) of Gram negative bacteria. This interaction causes a reduction
in membrane stability, pore formation, and eventual cell lysis (Ryu et al., 2014).
Cathelicidin functions within the lysosome of keratinocytes and directly targets the S.
aureus lipoprotein membrane to destroy the bacteria (Braff MH, 2005). In addition,
resident commensals such as S. epidermis and P. acnes inhabit the skin niche, thereby
occupying the space that would otherwise be available for S. aureus to bind the skin
(Lina et al., 2003). Furthermore, S. epidermis secretes a serine protease called Esp that
degrades specific S. aureus proteins known to be crucial for biofilm formation and
architecture, thereby hindering S. aureus growth (Sugimoto et al., 2013). Despite this
inhospitable environment, S. aureus is still able to colonize a large portion of the human
population, typically with little to no clinical concern, as long as the skin barrier is not
compromised.
Much of the ability of the skin to provide a barrier against pathogens is based on
the architecture of the tissue (Krishna and Miller, 2012a). The skin is divided into the
epidermis and the dermis (Figure 1.2). The surface layer of the epidermis is called the
corneal layer, which provides special protection against the environment. This layer is
developed though the process of keratinization, which is the formation of terminally
differentiated or dying keratinocytes filled with keratin and held tightly together by crosslinked fibrils.

The corneal layer is not present in other epithelia exposed to the

environment such as in the lungs or the gut. Below the corneal layer are the granular,
spinous, and basal layers of the epidermis (Krishna and Miller, 2012a). As keratinocytes
originate in the basal layer and migrate upward to the corneal layer, they continuously
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reform the surface of skin, providing maintenance of this defense system. Below the
epidermis is the dermis, which is composed of collagen and elastin fibers as well as many
cell types that are important for innate immune defense (addressed below) (Kupper and
Fuhlbrigge, 2004). The dermis can be further subdivided into the papillary layer, which
connects to the epidermis and the deeper reticular layer, which in turn connects to
adipose and muscle tissue. The epidermis and the dermis layers are spanned by hair
follicles, sweat glands and sebaceous glands, which are called skin appendages and are
open to the surface (Nestle et al., 2009). These appendages excrete free fatty acids which
lead to acidification of the skin. Another important component of the skin includes the
capillary and lymphatic vessels. These vessels are portals for immune cell recruitment
and antigen surveillance (Tay et al., 2014). Therefore, the skin has a complex architecture
providing an important barrier against pathogens.
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Figure 1.2. Structure of the Skin.
The surface of the skin has mechanisms to prevent infection such as low pH and low
temperature, production of antimicrobial peptides by keratinocytes, resident commensals,
and the physical barrier of the epidermis. Within the dermis reside skin and immune cells,
such as resident macrophages, Langerhans, and B and T cells. During an infection,
keratinocytes and immune cells produce inflammatory cytokines to promote the
recruitment of neutrophils from the bloodstream. Also, lymphatic vessels innervate the
skin to allow for antigen surveillance. Adapted from (Miller and Cho, 2011).

13

Innate immune recognition and response to S. aureus skin infection
The innate immune response to S. aureus is a multi-faceted response to promote
clearance of the bacteria from the skin (Miller and Cho, 2011). The response includes
cytokine production to activate local immune cells and chemokine production to recruit
and activate neutrophils and other professional phagocytic cells.

In addition to the

physical barrier of the skin described above, the dermis also contains within it an
immunological barrier (Kupper and Fuhlbrigge, 2004). This barrier is composed of
immune cells, such as Langerhans dendritic cells, resident tissue macrophages and B and
T lymphocytes, that conduct surveillance for pathogens by detecting pathogen-associated
molecular patterns (PAMPs) (Nestle et al., 2009). PAMP motifs include bacterial surface
components such as lipoteichoic acid (LPS) and LTA, as well as flagellin, each of which
the host immune system recognizes as “non-self” (Akira and Takeda, 2004). These
PAMPS are detected by pattern recognition receptors (PRR) which can be categorized by
location and ligand specificity. For sensing S. aureus in the extracellular environment
PRRs called Toll-Like Receptors (TLR), specifically TLR1 and TLR2, are present on the
host cell surface and recognize components of the bacterial cell wall (Akira and Takeda,
2004). During infection with S. aureus, keratinocytes recognize LTA as it binds to TLR2
triggering the MyD88 signaling pathway, which signals internally via TRAF6 to activate
transcription of cytokines via NF-κB (Newton and Dixit, 2012). For sensing S. aureus in
the intracellular environment, keratinocytes also express cytoplasmic nod-like receptor 2
(NOD2) which detects the breakdown product of S. aureus peptidoglycan, called
muramyl-dipeptide (Girardin et al., 2003). Activation of these PRRs leads to initiation of
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the host innate immune response, which begins with cytokine and chemokine production
(Miller and Cho, 2011).
Upon detection of S. aureus PAMPS, keratinocytes release the cytokines IL-1α,
IL-1β and IL-17, and the chemokines CXCL1, CXCL2, and IL-8 (Krishna and Miller,
2012b). IL-1α is stored within keratinocytes and released during infection, whereas IL1β secretion is induced by activation of the NLRP3 inflammasome after Hla forms a pore
in the host cell membrane (depicted in Figure 1.3) (Craven et al., 2009; Munoz-Planillo et
al., 2013). The IL-1 cytokines bind to the IL-1 receptor (IL-1R), leading to activation of
the MyD88 signaling pathway (Miller and Cho, 2011). The importance of the IL-1
cytokine family has been demonstrated clinically, as humans with deficiencies in the IL1R signaling pathway are susceptible to repeated S. aureus skin infections (van de
Veerdonk and Netea, 2013) (Picard et al., 2010). In addition, IL-17 has also been shown
to be important for protection against S. aureus skin infections, as mice deficient in the
IL-17 receptor A (IL-17RA) have impaired clearance of S. aureus (Cho et al., 2010).
Furthermore, IL-1α secretion and signaling causes CXCL1, CXCL2 and IL-8 production
in order to recruit neutrophils from circulation to combat infection (Olaru and Jensen,
2010).
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Figure 1.3. Production of IL-1β via activation of the NLRP3 inflammasome.
IL-1β is secreted following activation of two signaling pathways. Signal 1: TLR2 is
activated by cell wall components of S. aureus, such as peptidoglycan (PGN) and
lipoteichoic acid LTA), leading to pro-IL-1β production. Signal 2: Alpha hemolysin (Hla)
forms a pore in the cell membrane, causing potassium efflux, leading to activation of the
NLRP3 inflammasome. This results in cleavage and activation of caspase-1, which in
turn cleaves pro-IL-1β, resulting in active IL-1β secretion. Adapted from (Gattorno and
Martini, 2013).
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Once the pro-inflammatory signaling cascades are activated, neutrophils are
recruited to the site of infection to participate in abscess formations (Cho et al., 2012a).
The abscess is primarily composed of neutrophils and bacteria surrounded by
macrophages, creating a closed environment (Kobayashi et al., 2015).

The abscess

structure isolates the pathogen and noxious neutrophil killing components in one location,
to prevent the spread of infection and to prevent damage to nearby healthy tissue
(Kobayashi et al., 2015). Within the abscess, neutrophils use multiple mechanisms to kill
bacteria including the release of neutrophil extracellular traps (NETs), secretion of
antimicrobial peptides, proteinases, and acid hydrolases (Molne et al., 2000). NETs are
composed of both webs of DNA that function to capture the bacteria as well as release a
high concentration of antimicrobial effectors to kill the bacteria (Pilsczek et al., 2010).
At the site of infection, neutrophils empty the contents of their azurophilic granules to
release antimicrobial proteins, such as cathepsin G and neutrophil elastase to kill
extracellular S. aureus (Segal, 2005). Bacteria engulfed by neutrophils are killed within
the phagosome by antimicrobial peptides, degradative enzymes and reactive oxygen
species (ROS).

ROS such as superoxide (O2-) and hydrogen peroxide (H2O2), are

generated by the NADPH oxidase in a mechanism called oxidative burst, (depicted in
Figure 1.4) (Nauseef, 2007).

Other ROS such as hyperchlorous acid (HOCl) are

produced via the activity of myeloperoxidase (Kobayashi et al., 2015). The importance of
the NADPH oxidase is highlighted clinically in that patients with chronic granulomatous
disease, who have defective oxidative burst due to a genetic mutation causing defective
subunits of the NADPH oxidase to be produced, have significantly increased
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susceptibility to S. aureus infections (Bouma et al., 2010). Therefore, the rapid and
potent neutrophil response to S. aureus is crucial to combating infection.
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Figure 1.4. Neutrophil killing of S. aureus.
At the site of infection neutrophils phagocytose S. aureus. Within the phagosome, the
neutrophils produce antimicrobial peptides, degradative enzymes, and reactive oxygen
species (ROS) in order to kill the bacteria. Specifically, ROS are produced via the
function of the NADPH oxidase. Adapted from (Kobayashi et al., 2015).
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Regulation of the innate immune response to S. aureus
Once the initial assault against S. aureus is complete, regulation of the inflammatory
immune response becomes crucial, as an unregulated response could lead to collateral
damage to surrounding healthy tissue if the inflammation is allowed to persist (Wilgus et
al., 2013). Although this has previously not been investigated with respect to skin
infection, one plausible control mechanism is via recruitment of macrophages to the site
of infection to clear apoptotic neutrophils before they become necrotic and release
noxious intracellular components such as elastase, proteases, activated caspases, and
signaling components such as danger associated molecular patters (DAMPs) (Silva, 2010,
2011).

In general, neutrophil clearance occurs through macrophage recognition of

phosphatidylserine (PS) on the surface of the apoptosing neutrophils (Fadok et al., 1998),
followed by the formation of a thrombospondin bridge between CD36 on the macrophage
and αv𝛽 3 integrin on the neutrophil (Savill et al., 1992). Once the apoptosing neutrophils
are cleared from the infection site, the environment surrounding the abscess could shift
into a wound healing stage modulated by macrophages, and with new tissue formation
and remodeling as keratinocytes proliferate (Rodero and Khosrotehrani, 2010).

In

Chapter 3 of this dissertation, we directly investigate the importance of CD36 in
controlling the innate immune response to S. aureus skin infection.
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Part 2: The role of CD36 in combating S. aureus infection and inflammation

Discovery and characterization of CD36
CD36 is a transmembrane cell surface protein and was first isolated from platelets
(Clemetson et al., 1977). Since then, CD36 has been recognized as a multi-functional
scavenger receptor expressed on the plasma membrane of many cells types, including
microvascular endothelial cells, macrophages, and adipocytes (Silverstein and Febbraio,
2009). CD36 has many other names including glycoprotein IV (gpIV) and fatty acid
translocase (FAT), and it is categorized as a member of the class B scavenger receptor
family (Park, 2014). In humans, cd36 is found on chromosome 7q11.2 and encodes a
53kD protein that undergoes extensive post-translational modification, including
glycosylation, leading to a size of 88kD when expressed on the cell surface (Park, 2014;
Silverstein and Febbraio, 2009).

It has two transmembrane regions and a single

extracellular region (depicted in Figure 1.5) with many ligand binding domains that bind
numerous endogenous and exogenous ligands (Armesilla and Vega, 1994; Silverstein and
Febbraio, 2009). For example, thrombospondin binds the extracellular amino acids 93120, which has been shown to be important in macrophage recognition of apoptotic
neutrophils (Savill et al., 1992). Oxidized low density lipoprotein (oxLDL) binding of
amino acids 120-155 (Podrez et al., 2000) has been shown to be important for foam cell
formation leading to atherosclerosis and cardiovascular disease (Silverstein, 2009). Long
chain fatty acids bind CD36 in a small binding pocket and are engulfed by CD36
expressing adipocytes, implicating CD36 as a fatty acid transport receptor (Ibrahimi and
Abumrad, 2002).
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Figure 1.5. Structure of CD36.
CD36 is a transmembrane receptor with two short intracellular regions and one large
extracellular domain with binding sites for thrombospondin, oxLDL and fatty acids.
Adapted from (Park, 2014)
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Anti-bacterial functions of CD36
In addition to the roles discussed above, CD36 also plays an important role in host
defense. The first data showing that CD36 has a role in combating S. aureus infections
came from the discovery that CD36 is a co-receptor for TLR2, and is required for
detection of LTA from S. aureus (Hoebe et al., 2005b). Mice with genetic knockouts of
CD36 are unable to contain S. aureus infection, as indicated by imaging showing
increased dissemination of luminescent S. aureus after subcutaneous injection (Hoebe et
al., 2005b). Therefore, it was concluded that CD36 plays an important function in host
innate immune detection of S. aureus. This concept was expanded upon in another study
where it was demonstrated that CD36 is not only important for sensing S. aureus, but also
key to phagocytosis of S. aureus and LTA (Stuart et al., 2005). The C-terminal domain of
CD36 signals in conjunction with TLR2 to initiate cytoskeleton rearrangement for
engulfment of the bacteria, and triggers a TNF-α/IL-12 cytokine response to infection.
Additionally, mice with genetic knockouts of CD36 had increased susceptibility to S.
aureus bacteremia and reduced bacterial clearance (Stuart et al., 2005). However, the
role of CD36 in combating S. aureus skin infections has not been directly investigated.
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Part 3: The role of estrogen in combating S. aureus

Characterization of sex bias in susceptibility to infection
Epidemiological studies have shown that males are at an increased risk of many
bacterial infections compared to females (McClelland and Smith, 2011; Silva, 2011). It
is not known if this is due to differences in behavior, physiological differences in
susceptibility to infection, or a combination of these and possibly other factors (GuerraSilveira and Abad-Franch, 2013). If the sex bias is caused by a difference in behavior,
then this may be due differences in hand washing (Johnson et al., 2003) or, in the case of
skin infection, differences in physical activity that could lead to breaks in the skin barrier
(Collins and O'Connell, 2012). If genetics and physiological differences also contribute
to the sex bias in infection susceptibility, then this suggests that a dimorphic host immune
response to bacterial infection exists.
Sexual dimorphism in infectious diseases has been noted in epidemiological studies
and in animal models (McClelland and Smith, 2011), some of which are highlighted in
Table 1. For example, it has been well documented that males are more susceptible to
pulmonary M. tuberculosis, due in part to a reduced production of IgM antibodies and the
influence of sex hormones (Nhamoyebonde and Leslie, 2014). Males are also more
susceptible to Treponema pallidum, the causative agent of syphilis, due to a reduced
CD3+, CD4+ and CD8+ T lymphocytes compared to females (Pope et al., 1994).
Additionally, differing responses between the sexes to infection with fungi, parasites, and
viruses have been documented indicating that sex plays an important large role in
response to infection (Bernin and Lotter, 2014; McClelland and Smith, 2011). In
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addition, recent studies have shown that compared to females, males of all ages exhibit an
increased susceptibility to impetigo, which are blistering sores around the neck and face
indicative of a contagious skin infection (Kim et al., 2011). Additionally studies have
shown that males develop more methicillin-resistant S. aureus (MRSA) blood stream
infections than females (Savill et al., 1989). Although basic research in this area is
currently lacking, these clinical reports suggest that males may also have increased
susceptibility to S. aureus skin infections compared to females.
Limited studies suggest that females may be innately protected against S. aureus
infection. For example, during a study in rabbits with artificial chambers implanted
subcutaneously within the lumbar region, scientists realized that male rabbits were more
susceptible to S. aureus infection compared to female rabbits (Best et al., 1984). To
determine if sex hormones were responsible for the difference in susceptibility to S.
aureus, using the same artificial chamber model they infected ovariectomized female
rabbits and castrated male rabbits and found that neutered rabbits of both sexes had
comparable susceptibility to S. aureus infection, indicating that estrogen plays an
important role in protection against S. aureus infection (Best et al., 1984). A more recent
study in vitro demonstrated that alveolar macrophages from female mice were better able
to kill internalized S. aureus compared to macrophages from males due to increased
expression of nitric oxide synthase 3 (NOS3) (Yang et al., 2014), which generates nitric
oxide that is toxic to pathogens (Burgner et al., 1999). However, these two studies do not
address sex bias susceptibility during S. aureus skin infections, which is the most
common infection caused by this pathogen (Moran GJ and LK, 2006). Taken together,
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these data highlight the need to determine whether estrogen protects against S. aureus
skin infection.
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Male
Male
Male
Male
Post-menopausal
Female
Male

Cornebacterium kutscheri
Treponeuma pallidum
Listeria monocytogenes
Vibrio vulnificus
Borrelia burgdorferi
Humans

Mice
Humans
Mice
Humans
Humans

Mice
Rabbit

Susceptibility
Observed In

Lungs

Lungs
Artificial Chamber
Implant Near Lumbar
GI
Blood
GI
GI
Skin

Site of Infection

Table 1.1 Examples of bacterial infections with an observed sex bias in susceptibility.

Mycobacterium tuberculosis

Male
Male

More Susceptible
Sex

Mycobacterium marinum
Staphylococcus aureus

Pathogen

(Nhamoyebonde and
Leslie, 2014)

(Komukai et al., 1999)
(Pope et al., 1994)
(Pung et al., 1985)
(Kuo-Chou et al., 2010)
(Jarefors et al., 2006)

(Yamamoto et al., 1991)
(Best et al., 1984)

Reference

Cellular responses to estrogen
To better understand the sex bias to infection, and the contribution of estrogen to the
innate immune response, it is important to know how estrogen modulates gene expression
and cellular function. Estrogen is a steroid sex hormone mainly studied for development
of the female reproductive system (Jensen and DeSombre, 1972).

Estrogen is

synthesized from androstenedione, a cholesterol precursor (Cui et al., 2013). There are
three types of estrogen produced depending on the stage of reproduction (Figure 1.6):
estrone (E1) is produced during menopause, estradiol (E2), the predominant form, is
produced during child-bearing years, and estriol (E3) is produced during pregnancy (Cui
et al., 2013; Vrtacnik et al., 2014). In females, estradiol is produced in the ovaries,
breasts, adrenal gland, adipocytes and the liver, and serum concentration ranges from 20350 pg/mL during child-bearing years (Kratz et al., 2004).

In males, estradiol is

produced in the testis and sera concentration ranges from 0-20 pg/mL (Kratz et al., 2004).
Estrogen induced signaling occurs when it binds to any of the three estrogen receptors
ERα, ERβ, and GPR30 (Kovats, 2015). Estrogen receptors ERα and ERβ can form
heterodimers or homodimers during ligand binding (Vrtacnik et al., 2014). Estrogen
binding to these receptors leads to activation of either the classical or non-classical
signaling pathway. The classical pathway is where ERα and/or ERβ directly trigger gene
expression by binding to the Estrogen Response Element (ERE) found in the promoter of
various genes. For the non-classical pathway, the receptors work as scaffolds for other
transcription factors, such as AP-1, to bind promoter regions of DNA and trigger gene
expression. The recently discovered G-protein coupled receptor 30 (GPR30/GPER) is
found in the endoplasmic reticulum (Prossnitz et al., 2008). When estrogen binds this
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receptor, it triggers non-genomic signaling pathways, such as activation of the second
messengers calcium, cAMP and nitric oxide, as well as signaling cascades through PI3K
and AKt (Revankar et al., 2005). Activation of these signaling pathways through may be
important for host defense against S. aureus, since sex hormones have been demonstrated
to have an important role in combating other bacterial infections (Garcia-Gomez et al.,
2013; Kanda and Watanabe, 2005).
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Figure 1.6. Structures of the three main types of estrogens.
Estrogen is a sex steroid hormone exhibiting the classical 4 ring steroid structure.
Estrone has a ketone group attached to the D ring, while estradiol has one hydroxyl group
attached to the D ring and estriol has two hydroxyl groups attached to the D ring.
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Part 4: Concluding remarks and hypotheses
Given that S. aureus is the major cause of SSTI (Moran GJ and LK, 2006), the
work described in this dissertation will focus on advancing our understanding of the
innate immune response to these infections, specifically with respect to control of the
inflammatory response (CD36) and natural resistance (estrogen). First, CD36 has been
shown to aid in phagocytosis of S. aureus as a co-receptor for TLR2 (Hoebe et al.,
2005b) and is also important for the general clearance of apoptotic neutrophils (Fadok et
al., 1998). However, the contribution of this receptor to the regulation of the host
immune response to S. aureus skin infection has not been investigated. We hypothesized
that, independent of its role in bacterial phagocytosis, CD36 on macrophages would play
a significant role in regulating local inflammation and dermonecrosis during S. aureus
skin infection (depicted in Figure 1.7). The experimental studies to test this hypothesis
are discussed in Chapter 3. Second, estrogen has been shown to be important for reduced
susceptibility to some infectious diseases (Garcia-Gomez et al., 2013; Kanda and
Watanabe, 2005), however, the contribution of this sex hormone to protection against S.
aureus skin infection has not been investigated. We hypothesized that estrogen mediates
protection against S. aureus skin and soft tissue infections by increasing bacterial
clearance leading to reduced pathogenesis (depicted in Figure 1.8). The experimental
studies to test this hypothesis are discussed in Chapter 4.
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Figure 1.7. Roles of CD36 in host defense.
Cellular CD36 functions as a co-receptor with TLR2 to recognize lipoteichoic acid or
peptidoglycan leading to phagocytosis of S. aureus. Expression of CD36 is regulated by
binding of oxidized LDL or agonists for peroxisome proliferating activated receptor
(PPARγ), which acts as a transcription factor binding to retinoid X receptor (RXR).
CD36 binds to thrombospondin which functions as a bridge from the macrophage to
apoptotic neutrophils expressing phosphatidylserine (PS), the “eat me” signal, resulting in
clearance of dying neutrophils. It is unknown if CD36 contributes to regulation of the
host inflammatory response to Hla producing S. aureus.
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Figure 1.8. Roles of estrogen in host defense.
Estrogen leads to cell signaling when it binds to any of the three estrogen receptors ERα,
ERβ, and GPR30 (Kovats, 2015). Estrogen receptors ERα and ERβ can form
heterodimers or homodimers during ligand binding (Vrtacnik et al., 2014), which can
then directly trigger gene expression by binding to the Estrogen Response Element (ERE)
found in the promoter of various genes or by functioning as scaffolds for other
transcription factors to bind promoter regions of DNA and trigger gene expression.
GPER is found in the endoplasmic reticulum (Prossnitz et al., 2008), and estrogen
binding leads to calcium mobilization, activation of cAMP and signaling cascades
through PI3K pathways. It is unknown if estrogen through these signaling pathways aids
in host defense against S. aureus.
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Chapter 2 Methodology
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The purpose of this chapter is to provide detailed protocols for the studies conducted in
Chapter 3 and Chapter 4.

Bacterial Strains
S. aureus USA300 LAC and its isogenic agr-deletion mutant (LACagr) were provided
by Dr. Frank DeLeo (Rocky Mountain Laboratories, NIH/NIAID) and Dr. Michael Otto
(NIH/NIAID). The isogenic hla deletion mutant (LAC

) was generously provided by

Dr. Juliane Bubeck-Wardenburg (University of Chicago). The studies conducted in
Chapter 3 use LAC, LACagr, and LAC

strains. The studies in Chapter 4 use the

LAC strain.

Bacterial Growth Conditions
Bacteria for skin infection were used at early exponential phase and prepared as
previously described with minor modifications (Rothfork et al., 2003). To generate
bacteria at this phase, 25 mL cultures in trypticase soy broth (TSB) were inoculated and
grown for 16-18 hours at 37°C with shaking at 240 rpm in a 50 mL conical tube. The
bacteria were then pelleted by centrifugation at 1800x g for 4 minutes at 4°C.
Supernatant was discarded and the pellet was washed twice with cold saline, then
resuspended in 1 mL TSB and vortexed. Twenty-five microliters of this bacterial stock
was used to inoculate a fresh 25 mL culture and grown for 2 hours at 37°C with shaking
at 240 rpm in a 50 mL conical tube. Following incubation, bacteria were again pelleted
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by centrifugation at 1800 x g for 4 minutes at 4°C. Supernatant was discarded and the
pellet was washed three times with cold saline, then resuspended in 1 mL TSB and
vortexed. Twenty-five microliters of this bacterial stock was used to inoculate a fresh 25
mL culture and grown for 2 hours at 37°C with shaking at 240 rpm in a 50mL conical
tube. Following incubation, bacteria were again pelleted by centrifugation at 1800 x g for
4 minutes at 4°C. Supernatant was discarded and the pellet was washed three times with
cold saline, then resuspended in 1 mL TSB and vortexed. Two hundred microliters of
this bacterial solution was used to inoculate a fresh 25 mL culture and grown for another
2 hours at 37°C with shaking at 240 rpm in a 50 mL conical tube. After this incubation,
bacteria were pelleted by centrifugation at 1800x g for 4 minutes at 4°C. Supernatant
was discarded and the pellet was washed twice with cold saline, then resuspended in 1
mL TSB and vortexed. Three hundred microliters of bacteria were used to inoculate a
fresh 25 mL culture and grown for a final 2 hours at 37°C with shaking at 240 rpm in a
50 mL conical tube. Bacteria were pelleted by centrifugation at 1800 x g for 4 minutes at
4°C and resuspended in 2 mL TSB/10% glycerol, sonicated for 30 seconds, and aliquoted
in 100 µL volumes and frozen at -80°C until use.
To prepare bacteria for infection, the frozen 100 µL aliquot was resuspended in
900 µL saline, and bacteria were pelleted by centrifugation at 12,500 rpm for 4 minutes at
4°C to wash out the glycerol. The pellet was resuspended in 1 mL saline, vortexed for 30
seconds, sonicated for 30 seconds, and diluted to an appropriate OD

600

for the desired

inoculum. In the Chapter 3 studies, a low inoculum of 8x106 CFUs/mouse or a higher
inoculum of 2x107 CFUs/mouse in 50 µL were used where indicated to infect mice. In
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the Chapter 4 studies, 2x107 CFUs/mouse in 50 µL were used to infect mice. CFUs were
verified by plating serial dilutions on blood agar (Becton Dickinson, Franklin Lakes, NJ).

Mice
Animal work in this study was carried out at the AAALAAC accredited Animal
Research Facility of the University of New Mexico Health Sciences Center in strict
accordance with recommendations in the Eighth Edition of The Guide for the Care and
Use of Laboratory Animals and the USA Animal Welfare Act. The protocol for these
studies was approved by the Institutional Animal Care and Use Committee (IACUC) of
the University of New Mexico. C57BL/6, BALB/c, and ovariectomized and sham surgery
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). CD36-/mice were bred within our facilities and breeders were provided by Dr. Maria Febbraio,
Ph.D., of the University of Alberta. All rights, title, and interest in the CD36-/- mice are
owned by Cornell University, where the CD36-/- mice were developed by Dr. Febbraio.

Skin Infection Model
We used a well-established model of S. aureus skin infection (Malachowa et al.,
2013). Twenty-four hours before infection, age-matched mice (8-12 weeks, 22-28 g)
were anesthetized by isoflurane and hair was removed from the right flank by first
shaving then applying Nair (Church and Dwight Co., NJ) for 1 minute followed by
rinsing with sterile water. For the studies conducted in Chapter 3, only male mice were
used. For the studies in Chapter 4, both male and female mice were used as indicated.
37

S. aureus

On the day of infection, 50

strain at the described inoculum was injected subcutaneously into the right flank of
anesthetized mice. Mice were weighed daily to assess weight loss as a marker of systemic
morbidity, and photographed for abscess and dermonecrosis development, which was
measured using ImageJ analysis (Schneider et al., 2012). This model is depicted in Figure
2.1.
For the intoxication experiments in Chapter 3, mice were subcutaneously injected
with 50 µL of supernatant of the indicated strain of S. aureus (Wright et al., 2005).
Supernatant was collected from a 5 mL culture grown in a 50 mL conical tube for 18
hours overnight at 37°C with shaking at 240 rpm. Cultures were normalized by OD 600
and centrifuged at 1800 x g for 4 minutes at 4°C to collect supernatant, which was then
passed through a 0.2 μM filter. The alpha-hemolysin (Hla) activity of the supernatant
was verified in rabbit red blood cell assay described below. For some intoxication
experiments, mice were subcutaneously injected with 1 µg of purified recombinant Hla or
mutant HlaH35L in 50 µL of sterile saline. Generation of recombinant Hla is described
below.
For the neutrophil depletion experiments in Chapter 3, CD36-/- mice were given
100 µg of anti-mouse Ly6G (Clone 1A8, BioXCell, West Lebanon, NH) or isotype
control (Rat IgG2a, BioXCell) by intraperitoneal injection on the day before and the day
of infection. Antibodies were dialyzed in PBS at 4°C overnight before use and total
protein concentration was confirmed by A280 using an extinction coefficient of 1.4 =
1mg/mL.
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Figure 2.1 Skin infection model.
Fur is removed and mice are infected just under the skin. Disease progression is
monitored, and samples are collected after mice are sacrificed (Malachowa et al., 2013).
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Tissue Collection
At the indicated time points, mice were sacrificed by CO2 asphyxiation, whole
blood was collected by cardiac puncture, and the abscesses (area = 2.25 cm 2) and spleens
were collected by excision as previously described (Sully et al., 2014). Whole blood sat
at 4°C for 30 minutes before centrifugation at 10,000 rpm for 10 min at 22°C. Sera was
collected and stored at -80°C until use (Hall et al., 2013). For CFU determinations,
abscesses and spleens were collected in bead-beating tubes containing 2.3 mm
Zirconia/Silica beads (BioSpec Products Inc., OK) and 1 mL of HBSS- (Gibco, Grand
Island, NY) with 0.2% Human serum albumin (Sigma, St. Louis, MO) (Rothfork et al.,
2003). Human serum albumin was used to prevent protein binding to the tube wall (Sully
et al., 2014). Tissue was disrupted for 3 min in 1 min intervals using a Mini-Bead
Beater-24 (BioSpec Products Inc., OK). During the intervals the tubes were placed on
ice for cooling. Homogenates were diluted into PBS containing 0.1% Triton X-100 and
sonicated, followed by plating serial dilutions on blood agar (Hall et al., 2013). For
cytokine and western blot analyses, abscess homogenates were clarified by centrifugation
at 12,500 x g and supernatant was stored at -80°C until use as described below.
Preparation of collected abscesses for qPCR or single cell analysis by flow cytometry is
described below.

Rabbit red blood cell lysis assay
Hemolysis activity of bacterial supernatant or recombinant Hla was determined
using a rabbit red blood cell assay previously described (Bernheimer, 1988b). Sample
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was diluted serially in PBS and incubated at 37°C for 1 hour in a 4% solution of rabbit
red blood cells (Colorado Serum Co., Denver, CO). Red blood cell lysis was assessed
spectrophotometrically by OD450. The data were analyzed by nonlinear regression fit to a
four-parameter logistic curve and represented as the HA50, which equals 1/the dilution
required for 50% complete lysis (Daly et. al., 2015).

Cytokine Analysis

Cytokines were measured in clarified supernatant from homogenized abscesses
collected on days 1, 3, and 7 post-infection using custom designed multiplex assays
(Millipore, Billerica, MA) according to the manufacturer’s directions. For the assay,
clarified supernatant from homogenized abscesses were pre-diluted 1:5 in assay buffer
for the optimal range of measurement according to the standards provided. Cytokines
measured include: IL-1β, TNF-α, IL-6, CXCL1, and MIP2. These cytokines were also
measured in murine sera, and were nearly undetectable, so these data were not included
in the chapters. The multiplex assays were ran at the UNM CTSC T1 lab on the Bio-Plex
200 (Biorad).

Quantitative RT-PCR
Abscess tissue was collected in RNALater (Qiagen, Valencia, CA), weighed and
RNA was isolated using Qiazol according to manufacturer’s instructions. RNA was then
purified using RNeasy Kits (Qiagen) and stored at -80°C until use. cDNA was generated
by high capacity cDNA RT kit with RNAse inhibitor and random hexamer primers
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(Applied Biosystems, Foster City, CA) on a PTC-200 Peltier thermocycler (Biorad,
Hercules, CA). cDNA was stored at -80°C until use. qPCR was performed using an
ABI7000 Real Time PCR system with Taqman Gene Expression master mix (Applied
Biosystems), Prime Time Predesigned qPCR Assays for il-1beta, nlrp3, asc, caspase-1
(Integrated DNA technologies, Coralville, IA), and cDNA diluted 1:5 in RNase free
water on.

Gene expression was quantified using SDS RQ Manager Version 1.2.2

software (Applied Biosystems) relative to the housekeeping gene hprt.

MPO ELISA
Myeloperoxidase was measured in clarified supernatant from homogenized
abscesses with the ELISA Mouse Myeloperoxidase DuoSet kit (R&D systems,
Minneapolis, MN) according to manufacturer’s directions.

For the assay, clarified

supernatant from homogenized abscesses were pre-diluted 1:100 in PBS for the optimal
range of measurement according to the standards provided.

Western blot
Clarified abscess homogenates were rapidly thawed at 37°C and protein
concentrations determined by A280 (Nanodrop 1000 Spectrophotometer, Thermo Fisher
Scientific, Wilmington, DE). Equivalent amounts of total protein were separated by
SDS-PAGE on 16% Tris-Glycine gels (Novex Life Technologies, Grand Island, NY)
prior to transfer to polyvinylidene fluoride membranes for 1 hour at 4°C. Membranes
were blocked with 1% BSA in Tris-buffered saline (TBS) (20 mM Tris pH 7.5, 150 mM
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NaCl) for 30 min at 4°C, then probed with rabbit anti-mouse Caspase-1 p10 (Santa Cruz
Biotechnology Inc., TX) or rabbit anti-mouse IL-1β (Abcam, Boston, MA) antibodies for
1 h at 22°C. Unbound primary antibody was removed by repeated washing with TBST
(TBS with 0.1% Tween20). Membranes were developed using nitro-blue tetrazolium and
5-bromo-4-chloro-39-indolyphosphate (NBT/BCIP: Pierce Biotechnology Inc., Rockford,
IL) following incubation for 1 h at 22°C with goat anti-rabbit IgG-alkaline phosphatase
(AP) conjugated secondary antibody (Sigma, St. Louis, MO). Imaging was performed
using a Protein Simple FluorChem R imaging system (Protein Simple, Santa Clara, CA).

Single Cell Suspension from Skin
Abscess tissue was collected in MACs storage solution (Miltenyi Biotec Inc.,
Auburn, CA) and enzymatically digested in gentle MACs C tubes in a 5 mL solution of
350 µg/mL Liberase TL (Roche, Indianapolis, IN), 2 mg/mL Hyaluronidase (Sigma), and
0.25 kU/mL DNase (Sigma) in RMPI 1640 Media (ATCC, Manassas, VA) for 2 hours
while shaking at 37°C. Digestion was halted with addition of 2 mL of ice cold RPMI
(Manassas, VA) supplemented with 10% FBS. Single cell suspensions were prepared by
mechanical disruption in C tubes using the Gentle MACs Dissociator (Miltenyi Biotec)
followed by f
counts were determined by trypan blue staining using the TC 20 Automated Cell Counter
system (Biorad, Hercules, CA). Single cells suspension were used to identify cells of
interest and/or isolate specific cell populations as described below.
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Flow Cytometry
After generating a single cell suspension from skin as described above, cells were
centrifuged at 800 x g for 3 minutes and resuspended in 500 µL of cold 0.075% sodium
azide (Sigma), 0.5% BSA in PBS. The cells were then blocked for 30 minutes with 2%
BSA at 4°C, followed by a 1 hour incubation at 4°C with anti-mouse Ly6G (BioXCell,
West Lebanon, NH) conjugated to Alexa Fluor 488 (Protein labeling kit, Molecular
Probes Inc., Eugene, OR), anti-mouse CD36-Alexa Fluor 647 (Biolegend, San Diego,
CA), anti-mouse F4/80-PE (Abcam, Cambridge, MA), or isotype controls. Cells where
washed with PBS prior to analysis by flow cytometry (Accuri C6, BD Biosciences, San
Jose, CA). Data was analyzed using FlowJo vX software (FlowJo LCC, Ashland, OR).

Neutrophil Isolation
After generating a single cell suspension from skin as described above, Ly6G +
cells were isolated by positive selection with an anti-Ly6G MicroBead Kit with the
MiniMacs Seperator according to manufacturer’s instructions (Miltenyi Biotec Inc.).
Cells were eluted from the column in PBS, at pH 7.2 with 0.5% bovine serum albumin,
and 2 mM EDTA. The isolated Ly6G+ cells were then used on the neutrophil response
assay described below. This kit was also used to isolate neutrophils from murine bone
marrow.
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Neutrophil Response Assay
Mice were sacrificed by CO2 asphyxiation, femurs and tibias were exposed and
bone marrow was recovered by flushing bones with warm Dulbecco’s Modified Eagle’s
Medium (4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500
mg/L sodium bicarbonate) (ATCC) using a 26 gauge needle. Recovered cells were
centrifuged at 800 x g for 3 min, red blood cells were lysed by incubation in cold water
for 1 minute, and Ly6G+ cells (neutrophils) were isolated as described above.
Neutrophils were incubated in LAC supernatant for 1 h at 37°C and 5% CO2. Cell
supernatant was collected for cytokine analysis and stored at -80°C until use. Cells were
lysed with RLT buffer (Qiagen) and RNA purified using an RNeasy Mini Kit (Qiagen).
Purified RNA was stored at -80°C until use.

Peritoneal Macrophage Isolation
Mice were sacrificed by CO2 asphyxiation, skin was cleaned with 70% EtOH and
a large incision was made to expose the peritoneal lining. Mouse peritoneal macrophages
were collected by peritoneal lavage with 5 mL warm Dulbecco’s Modified Eagle’s
Medium (ATCC) followed by filtration through a 70
centrifuged at 800 x g for 3 min then resuspended in Dulbecco’s Modified Eagle’s
Medium with 10% FBS, 10 mM Hepes, 2 mM L-glutamine, 1% penicillin/streptomycin
prior to plating. Cells were incubated overnight at 37°C in 5% CO2.
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Macrophage Administration to Mice
Cultured peritoneal macrophages (collected above) were washed twice with
Dulbecco’s PBS to remove non-adherent cells.

Macrophages were collected in

Dulbecco’s PBS via scraping and enumerated using the TC 20 Automated Cell Counter
(Biorad). Macrophages (1.0 x 104 cells in 100
mice by subcutaneous injection near the site of intoxication. For phagocytosis inhibition,
adherent cells were first incubated with 10 M cytochalasin B or saline control for 1 hour
at 37°C + 5% CO2, and washed with Dulbecco’s PBS before injection into mice.

Macrophage phagocytosis and killing of S. aureus

Raw 264.7 cells were grown in Dulbecco’s Modified Eagle’s Medium with 10%
FBS, 10 mM Hepes, 2 mM L-glutamine, 100 U/mL penicillin and 100 ug/mL
streptomycin at 37°C in 5% CO2 (Peterson et. al., 2008). Twenty-four hours prior to the
assay, cells were washed with PBS and the medium replaced with DMEM with 10 mM
Hepes, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin and 10%
Charcoal stripped FBS (to limit cell exposure to hormones) (JR Scientific, Woodland,
CA). Prior to the assay, early exponential-phase LAC was cultured in 3 ml of TSB at
2x107 CFU/ml with 50 nM exogenous AIP1 (Biopeptide Co., San Diego, CA) at 37°C
while shaking for 5 hours. The bacteria were centrifuged, washed in PBS, sonicated, and
suspended at 2x108 CFUs/mL in DMEM with 10% Charcoal stripped FBS. The bacteria
were opsonized overnight with rabbit anti- S. aureus IgG at 100 µg/ml (Accurate
Chemical & Scientific Co., Westbury, NY) at 4°C on ice.
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On the day of the assay, RAW 264.7 cells were detached with Cell Stripper
(Corning, Manassas, VA), and enumerated using the TC 20 Automated Cell Counter
(Bio-rad) (Peterson et. al., 2008). Cells were resuspended at 2x107 cells/ml in DMEM
with 10% Charcoal stripped FBS and incubated with 500 nM or 5 µM 17-β Estradiol
(Sigma-Aldrich, St. Louis, MO) or vehicle control for 2 hours at 37°C in 5% CO2. The
cells were then combined with opsonized bacteria at a multiplicity of infection (MOI) of
10. The cells and bacteria were centrifuged at 500 x g for 3 min to initiate contact,
followed by incubation at 37°C in 5% CO2 for 1 hour to allow for phagocytosis. At 1
hour, lysostaphin (Sigma-Aldrich) was added at 2 µg/ml for 15 min to kill extracellular
bacteria and then removed by centrifugation and replaced with fresh medium. Half of the
samples were immediately processed for CFU determination to determine percent
phagocytosis relative to initial bacterial concentration, and the other half were incubated
for an additional 4 hours at 37°C in 5% CO2 before CFU enumeration to determine
percent killing. Bacteria were enumerated by dilution into PBS with 0.1% Triton X-100,
followed by sonication and plating onto blood agar.

Expression and purification of recombinant Hla and mutant H35L
The coding sequence for Hla was PCR amplified from USA300 LAC genomic
DNA using the following primers for insertion into the expression vector pET-28a(+)
(Novagen, EMD Millipore, Billerica, MA) using the 5’ NcoI and a 3’ XhoI restriction
sites: HylA F, 5'- GAGATACCATGGCAGATTCTGATATTAATATTAAAACCGG-3’
and HylA R,

5'- CATTATCTCGAGATTTGTCATTTCTTCTTTTTCCCAATCGAT
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TTTATATC-3’ (Integrated DNA Technologies, Coralville, IA). The resulting construct
includes an N-terminal methionine and a C-terminal poly-histidine tag (LEHHHHHH).
This construct was transformed into the cloning strain 5-alpha F’ Iq (New England
BioLabs, Ipswich, MA).

The H35L variant (HlaH35L) (Menzies et. al., 1994) was

constructed using Q5 Site Directed Mutagenesis Kit (New England Biolabs) according to
manufacturer’s instructions and using the following primers: Q5SDM F, 5'- ATGGATA
GAACTGAGCATCCAAACAACAAAC-3’ and Q5SDM R, 5'-AGTAATAACTGTAGC
GAAG-3’. The HlaH35L variant construct was inserted into pET-28a(+) (Novagen).
Both Hla constructs were transformed into BL21 Star (DE3) Competent E. coli
(Life Technologies, Grand Island, NY) for expression. Bacteria were grown in Terrific
Broth with 30 µg/mL kanamycin at 37 °C, 220 rpm and expression induced at an OD600
of 0.7 by 400 µM IPTG.

The biomass was harvested 3 hrs post-induction by

centrifugation and the cell pellet was frozen at -80 °C. The pellet was thawed in 5
volumes of lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 0.5 mg/mL lysozyme, 2 mM
EDTA, Pierce Universal Nuclease for Cell Lysis (Life Technologies), pH 8.0) and
incubated for one hour at 37°C with rotation. Remaining intact cells were lysed by
sonication and cellular debris removed by centrifugation (14000 x g for 30 min at 4 °C).
Clarified lysate was loaded on a GE Healthcare C 10/200 column containing Clontech
Talon Metal Affinity Resin (Mountain View, CA) pre-equilibrated in binding buffer (50
mM Tris-Cl, 150 mM NaCl, pH 8.0). After washing, bound protein was eluted with 50
mM Tris-Cl, 150 mM NaCl and 300 mM imidazole, pH 7.0. The eluted protein was then
further purified and buffer exchanged using a GE Healthcare Sephacryl S-400 16/60
prepacked column (Pittsburgh, PA) equilibrated in PBS. The final protein ran as a single
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band on SDS/PAGE (data not shown). Recombinant protein was filtered for endotoxin
removal (0.2 m Acrodisc® Unit with Mustang™ E membrane, Pall Life Science, Ann
Arbor, MI) and tested for endotoxin according to manufacturer’s directions
(ToxinSensor™ Chromogenic LAL Endotoxin Assay, GenScript, Piscataway, NJ) before
use. Total protein concentration was confirmed by A280 with extinction coefficient = 1.1.
The activity of Hla and the inactivity of HlaH35L were verified using the rabbit red blood
cell lysis assay as previously described (Bernheimer, 1988b).

Statistical Analysis
Statistical analyses were performed using Graph Pad Prism 6.0 software (Graph
Pad Software, Inc., La Jolla, CA). In vitro data were analyzed by Student’s t test and in
vivo results by the Mann-Whitney U test for non-parametric data.
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Abstract
Staphylococcus aureus is the primary cause of skin and skin structure infections
(SSSI) in the USA. Alpha-hemolysin (Hla), a pore-forming toxin secreted by S. aureus
and a major contributor to tissue necrosis, prompts recruitment of neutrophils critical for
host defense against S. aureus infections. However, the failure to clear apoptotic
neutrophils can result in damage to host tissues, suggesting that mechanisms of
neutrophil clearance are essential to limiting Hla-mediated dermonecrosis. We
hypothesized that CD36, a scavenger receptor which facilitates recognition of apoptosing
cells, would play a significant role in regulating Hla-mediated inflammation and tissue
injury during S. aureus SSSI. Here we show that CD36 on macrophages negatively
regulates dermonecrosis caused by Hla-producing S. aureus. This regulation is
independent of bacterial burden, as CD36 also limits dermonecrosis caused by
intoxication with sterile bacterial supernatant or purified Hla. Dermonecrotic lesions of
supernatant intoxicated CD36-/- mice are significantly larger, with increased neutrophil
CD36+/+ (wild-type) mice. Neutrophil

accumulation and IL-

depletion of CD36-/- mice prevents this phenotype, demonstrating the contribution of
neutrophils to tissue injury in this model. Furthermore, administration of CD36+/+, but
not CD36-/-, macrophages near the site of intoxication reduces dermonecrosis, ILproduction and neutrophil accumulation to levels seen in wild-type mice. This therapeutic
effect is reversed by inhibiting actin polymerization in the CD36+/+ macrophages,
supporting a mechanism of action whereby CD36-dependent macrophage phagocytosis
of apoptotic neutrophils regulates Hla-mediated dermonecrosis. Together, these data
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demonstrate that CD36 is essential for controlling the host innate response to S. aureus
skin infection.
Introduction
Staphylococcus aureus is the primary cause of skin and skin structure infections
(SSSI) presenting to emergency departments throughout the US (Moran et al., 2006;
Talan et al., 2011). SSSIs include an intense local inflammatory response, which often
precedes the formation of necrotic lesions. Although S. aureus secretes numerous
virulence factors, the formation of necrotic lesions is largely due to the action of the poreforming toxin alpha-hemolysin (Hla) (Inoshima et al., 2012; Kennedy et al., 2010;
Kobayashi et al., 2011b; Sampedro et al., 2014; Tkaczyk et al., 2013). In recent years, the
cellular receptor for Hla, the metalloprotease ADAM10, and its contribution to
dermonecrosis, has been well-characterized (Becker et al., 2014; Berube and
Wardenburg, 2013; Inoshima et al., 2011; Inoshima et al., 2012; Powers et al., 2012;
Sampedro et al., 2014; Wilke and Wardenburg, 2010). In contrast, little is known
regarding mechanisms used by the host to control local inflammation and limit Hlamediated tissue injury. Insight into these mechanisms of host control could inform novel
approaches to limit the pathogenesis of S. aureus SSSIs.
Neutrophils are critical for host defense against S. aureus and utilize a variety of
mechanisms to kill the bacteria to limit invasive infection (reviewed in (Rigby and
DeLeo, 2012)). However, neutrophils are short-lived and contain many noxious
substances which, if released, are toxic to host tissues (Soehnlein and Lindbom, 2010;
Weiss, 1989). Therefore, the clearance of apoptotic neutrophils, prior to the loss of
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membrane integrity during secondary necrosis, is essential to limiting tissue damage.
Importantly, Hla contributes to the recruitment of circulating neutrophils (Bartlett et al.,
2008), suggesting that mechanisms of neutrophil clearance are essential to limiting Hlamediated dermonecrosis.
The scavenger receptor CD36 is a membrane glycoprotein present on many
mammalian cells, in particular monocytes and macrophages (reviewed in (Silverstein and
Febbraio, 2009)), which is primarily known for its contribution to atherosclerosis (CollotTeixeira et al., 2007; Park, 2014). However, CD36 also contributes to host innate defense
against S. aureus. In conjunction with Toll-like receptor 2 (TLR2), CD36 recognizes S.
aureus cell wall diacylglycerides, facilitating bacterial phagocytosis and cytokine
production (Hoebe et al., 2005a; Stuart et al., 2005). Importantly, CD36 also enables
macrophage recognition and clearance of apoptotic neutrophils (Navazo et al., 1996; Ren
et al., 1995; Savill et al., 1991; Savill et al., 1992), suggesting an important role for CD36
in controlling the host response to skin infection; however the contribution of this
receptor to the regulation of Hla-mediated dermonecrosis has not been investigated. We
hypothesized that CD36 on macrophages would play a significant role in regulating local
Hla-mediated inflammation and dermonecrosis, independent of its role in bacterial
phagocytosis.
Using a mouse model of S. aureus dermonecrosis, here we show that CD36
negatively regulates dermonecrosis following infection with Hla-producing S. aureus. At
early time points post-infection, this regulation is independent of bacterial clearance, as
CD36 also limits dermonecrosis following subcutaneous intoxication with S. aureus
secreted virulence factors and purified Hla. CD36-/- mice intoxicated with sterile S.
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aureus supernatant show significantly increased dermonecrosis, with increased neutrophil
CD36+/+ (wild-type) mice. This

accumulation and local IL-

phenotype is prevented by neutrophil depletion, pointing to the contribution of
neutrophils to tissue injury in this model. Importantly, therapeutic administration of
CD36+/+, but not CD36-/-, macrophages near the site of intoxication limits dermonecrosis,
ILadministration of CD36+/+ macrophages significantly reduces the presence of necrotic
neutrophils at the site of intoxication, this is reversed by pharmacological blockade of
macrophage actin polymerization. This supports a mechanism of action whereby CD36mediated macrophage phagocytosis of apoptotic neutrophils plays a significant role in
host regulation of Hla-mediated dermonecrosis. Together, these data demonstrate for the
first time that, independent of its role in bacterial clearance (Stuart et al., 2005), CD36
expression on macrophages plays an important role in host control of inflammation and
skin injury during S. aureus skin infection.
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Materials and Methods

Bacterial strains and growth conditions
S. aureus USA300 LAC and its isogenic agr-deletion mutant (LACagr) were provided
by Dr. Frank DeLeo (Rocky Mountain Laboratories, NIH/NIAID) and Dr. Michael Otto
(NIH/NIAID). The isogenic hla deletion mutant (LAC

) was generously provided by

Dr. Juliane Bubeck-Wardenburg (University of Chicago). Bacteria were grown in
trypticase soy broth (TSB) at 37°C to early exponential phase as previously described
(Rothfork et al., 2004) and CFUs determined by plating serial dilutions on blood agar
(Becton Dickinson, Franklin Lakes, NJ).

Mouse model of S. aureus skin and soft tissue infection
Animal work in this study was carried out at the AAALAC accredited Animal Research
Facility of the University of New Mexico Health Sciences Center in strict accordance
with recommendations in the Eighth Edition of The Guide for the Care and Use of
Laboratory Animals and the USA Animal Welfare Act. The protocol was approved by
the Institutional Animal Care and Use Committee (IACUC) of the University of New
Mexico. C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME)
and CD36-/- mice, provided by Dr. Maria Febbraio, were bred within our facilities. The
mouse model of dermonecrosis was performed as previously described (Malachowa et
al., 2013). Briefly, twenty-four hours before infection, male, age-matched mice (8-12
weeks, 22-28 g) were anesthetized by isoflurane and hair was removed from the right
flank using Nair (Church and Dwight Co., Ewing, NJ). On the day of infection, 50
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sterile saline containing 8 x 106 CFUs of the indicated S. aureus strain was injected
subcutaneously into the right flank of anesthetized mice. Mice were weighed daily and
photographed for abscess and ulcer area which was measured using ImageJ analysis
(Schneider et al., 2012). At the indicated time points post-infection, mice were sacrificed
by CO2 asphyxiation and the abscesses (area = 2.25 cm2) and spleens were collected. For
CFU determinations, abscesses and spleens were collected in bead-beating tubes
containing 2.3 mm Zirconia/Silica beads (BioSpec Products Inc., Bartlesville, OK) and 1
mL of HBSS- (Gibco, Grand Island, NY) with 0.2% Human serum albumin (SigmaAldrich, St. Louis, MO). Tissue was disrupted for 3 min in 1 min intervals using a MiniBead Beater-24 (BioSpec Products Inc.). Homogenates were diluted into PBS containing
0.1% Triton X-100 and sonicated, followed by plating serial dilutions on blood agar. For
cytokine and western blot analyses, abscess homogenates were clarified by centrifugation
at 12,500 × g and supernatant was stored at -80°C until use as described below. For
intoxication experiments, mice were subcutaneously injected with 50 µL of 0.2 micron
filtered supernatant from an 18-hour culture of the indicated strain of S. aureus or with 1
µg of purified Hla in 50 µL of sterile saline. For neutrophil depletion experiments, CD36/-

mice were given 100 µg of anti-mouse Ly6G (Clone 1A8, BioXCell, West Lebanon,

NH) (Daley et al., 2008) or isotype control (Rat IgG2a, BioXCell) by intraperitoneal
injection on the day before and the day of infection.

Quantification of cytokines and MPO
Cytokines were measured in clarified supernatant from homogenized abscesses using
custom designed multiplex assays (Millipore, Billerica, MA) according to the
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manufacturer’s directions. Myeloperoxidase was measured in clarified supernatant from
homogenized abscesses with the ELISA Mouse Myeloperoxidase DuoSet kit (R&D
systems, Minneapolis, MN) according to manufacturer’s directions.

Expression and purification of recombinant Hla and mutant H35L
The coding sequence for the mature Hla was PCR amplified from USA300 LAC genomic
DNA using the following primers for insertion into the expression vector pET-28a(+)
(Novagen, EMD Millipore, Billerica, MA) using the 5’ NcoI and a 3’ XhoI restriction
sites: HylA F, 5'- GAGATACCATGGCAGATTCTGATATTAATATTAAAACCGG
and HylA R,

5'- CATTATCTCGAGATTTGTCATTTCTTCTTTTTCCCAATCGA

TTTTATATC (Integrated DNA Technologies, Coralville, IA).

The resulting construct

includes an N-terminal methionine and a C-terminal poly-histidine tag (LEHHHHHH).
This construct was transformed into the cloning strain 5-alpha F’ Iq (New England
BioLabs, Ipswich, MA). The H35L variant (HlaH35L) was constructed using Q5 Site
Directed Mutagenesis Kit (New England Biolabs) according to manufacturer’s
instructions

and

using

the

following

ATGGATAGAActgAGCATCCAAACAACAAAC

primers:
and

Q5SDM
Q5SDM

F,
R,

5'5'-

AGTAATAACTGTAGCGAAG. The HlaH35L variant construct was again inserted into
pET-28a(+) (Novagen). Both Hla constructs were transformed into BL21 Star (DE3)
Competent E. coli (Life Technologies, Grand Island, NY) for expression. Bacteria were
grown in Terrific Broth with 30 µg/mL kanamycin at 37 °C, 220 rpm and expression
induced by 400 µM IPTG at an OD600 of 0.7. The biomass was harvested 3 hrs postinduction by centrifugation and the cell pellet was frozen at -80 °C. The pellet thawed in
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5 volumes of lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 0.5 mg/mL lysozyme, 2 mM
EDTA, Pierce Universal Nuclease for Cell Lysis (Life Technologies), pH 8.0) and
incubated for one hour at 37°C with rotation. Remaining intact cells were lysed by
sonication and cellular debris removed by centrifugation (14000 x g for 30 min at 4 °C).
Clarified lysate was loaded on a GE Healthcare C 10/200 column containing Clontech
Talon Metal Affinity Resin (Mountain View, CA) pre-equilibrated in binding buffer (50
mM Tris-Cl, 150 mM NaCl, pH 8.0). After washing, bound protein was eluted with 50
mM Tris-Cl, 150 mM NaCl and 300 mM imidazole, pH 7.0. The eluted protein was then
further purified and buffer exchanged using a GE Healthcare Sephacryl S-400 16/60
prepacked column (Pittsburgh, PA) equilibrated in PBS. The final protein ran as a single
band on SDS/PAGE (data not shown). Recombinant protein was filtered for endotoxin
removal (0.2 m Acrodisc® Unit with Mustang™ E membrane, Pall Life Science, Ann
Arbor, MI) and tested for endotoxin according to manufacturer’s directions
(ToxinSensor™ Chromogenic LAL Endotoxin Assay, GenScript, Piscataway, NJ) before
use. The activity of Hla and the inactivity of HlaH35L were verified using the rabbit red
blood cell lysis assay as previously described (Bernheimer, 1988a).

Western blot analyses
Clarified abscess homogenates were rapidly thawed at 37°C and protein concentrations
determined by A280nm absorbance (Nanodrop 1000 Spectrophotometer, Thermo Fisher
Scientific, Wilmington, DE). Equivalent amounts of total protein were separated by SDSPAGE on 16% Tris-Glycine gels (Novex Life Technologies, Grand Island, NY) prior to
transfer to polyvinylidene fluoride membranes. Membranes were blocked with 1% BSA
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in Tris-buffered saline (20 mM Tris pH 7.5, 150 mM NaCl) for 30 min at 4°C, then
probed with rabbit anti-mouse Caspase-1 p10 (Santa Cruz Biotechnology Inc., Dallas,
TX) or rabbit anti-mouse IL-1β (Abcam, Cambridge, MA) antibodies for 1 h at 22°C.
Unbound primary antibody was removed by repeated washing with TBST (TBS with
0.1% Tween20). Membranes were developed using nitro-blue tetrazolium and 5-bromo4-chloro-39-indolyphosphate (NBT/BCIP: Pierce Biotechnology Inc., Rockford, IL)
following incubation with goat anti-rabbit IgG-alkaline phosphatase (AP) conjugated
secondary antibody (Sigma-Aldrich, St. Louis, MO). Imaging was performed using a
Protein Simple FluorChem R imaging system (Protein Simple, Santa Clara, CA).

Quantitative RT-PCR
Abscess tissue (area = 2.25 cm2) was collected in RNALater and RNA isolated using
Qiazol according to manufacturer’s instructions (Qiagen, Valencia, CA). RNA was
purified using RNeasy Kits (Qiagen) and stored at -80°C until use. cDNA was generated
by high capacity cDNA RT kit with RNAse inhibitor and random hexamer primers
(Applied Biosystems, Foster City, CA) on a PTC-200 Peltier thermocycler (Bio-Rad,
Hercules, CA). qPCR was performed using Taqman Gene Expression master mix
(Applied Biosystems) and an ABI7000 Real Time PCR system. Gene expression was
quantified using SDS RQ Manager Version 1.2.2 software (Applied Biosystems) relative
to hprt or gapdh using Prime Time Predesigned qPCR Assays for il-1beta, tnf, cxcl1,
nlrp3, asc and caspase-1 (Integrated DNA technologies, Coralville, IA).
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Flow cytometry
Abscess sections were collected in MACs storage solution (Miltenyi Biotec Inc., Auburn,
CA) and enzymatically digested in gentle MACs C tubes using 350ug/mL Liberase TL
(Roche, Indianapolis, IN), 2mg/mL Hyaluronidase (Sigma-Aldrich), and 0.25 kU/mL
DNase (Sigma-Aldrich) in RMPI 1640 Media (ATCC, Manassas, VA) for 2 hours while
shaking at 37°C. Digestion was halted with ice cold RPMI (Manassas, VA) supplemented
with 10% FBS. Single cell suspensions were prepared by mechanical disruption in C
tubes using the Gentle MACs Dissociator (Miltenyi Biotec) followed by filtration
ead counts were
determined by trypan blue staining using the TC 20 Automated Cell Counter system
(Bio-Rad, Hercules, CA). Cells were centrifuged 800 × g for 3 minutes and resuspended
in cold 0.075% sodium azide (Sigma-Aldrich), 0.5% BSA in PBS and blocked for 30
minutes with 2% BSA, followed by a 1 hour incubation at 4°C with anti-mouse Ly6G
(BioXCell, West Lebanon, NH) conjugated to Alexa Fluor 488 (Protein Labeling Kit,
Molecular Probes Inc., Eugene, OR), anti-mouse CD36-Alexa Fluor 647 (Biolegend, San
Diego, CA), anti-mouse F4/80-PE (Abcam), or isotype controls. Where indicated, Ly6G+
cells were isolated with an anti-Ly6G MicroBead Kit according to manufacturer’s
instructions (Miltenyi Biotec Inc.). Cells were washed with PBS prior to analysis by flow
cytometry (Accuri C6, BD Biosciences, San Jose, CA). Data was further analyzed using
FlowJo vX software (FlowJo LCC, Ashland, OR).
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Bone marrow-derived neutrophils
Mouse femurs and tibias were collected and bone marrow recovered by flushing with
warm Dulbecco’s Modified Eagle’s Medium (4 mM L-glutamine, 4500 mg/L glucose, 1
mM sodium pyruvate, and 1500 mg/L sodium bicarbonate) (ATCC) using a 26-gauge
needle. Recovered cells were centrifuged at 800 × g for 3 min and Ly6G+ cells
(neutrophils) isolated as described above. Neutrophils were incubated in LAC
supernatant for 1 h at 37°C and 5% CO2. Cell supernatant was collected for cytokine
analysis or cells were lysed with RLT buffer (Qiagen) and RNA purified using an
RNeasy Protect Mini Kit (Qiagen). Purified RNA was stored at -80°C until use for qPCR.

Peritoneal macrophages
Mouse peritoneal macrophages were collected by peritoneal lavage with 5 mL warm

cell strainer. Cells were centrifuged at 800 × g for 3 min then resuspended in Dulbecco’s
Modified Eagle’s Medium with 10% FBS, 10mM Hepes, 2mM L-glutamine, 1%
penicillin/streptomycin prior to plating and overnight incubation at 37°C in 5% CO2.
Cells were washed twice with Dulbecco’s PBS to remove non-adherent cells.
Macrophages were collected in Dulbecco’s PBS via scraping and enumerated using the
TC 20 Automated Cell Counter (Bio-Rad). Macrophages (1.0 × 104
were administered to LAC intoxicated mice by subcutaneous injection adjacent to the site
of intoxication. For phagocytosis inhibition, adherent cells were incubated with 10 M
cytochalasin B or saline control for 1 hour at 37°C + 5% CO2, and washed with
Dulbecco’s PBS before injection into mice.
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Statistical analysis
Statistical analyses were performed using Prism 6.0 software (Graph Pad Software, Inc.,
La Jolla, CA). In vitro data were analyzed by Student’s t test and in vivo results by the
Mann-Whitney U test for non-parametric data.
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Results
CD36 limits dermonecrosis during S. aureus SSSI
To determine whether CD36 contributes to limiting pathogenesis during S. aureus
SSSI, we infected C57BL/6 (wild-type) and CD36-/- mice by subcutaneous injection with
the CA-MRSA USA300 isolate LAC. Compared to wild-type mice, CD36-/- mice had
significantly larger abscesses and increased dermonecrosis on days 1-7 post-infection
(Fig. 3.1A). Importantly, at the apex of dermonecrosis on day three post-infection, there
was no difference in local bacterial burden between CD36-/- and wild-type mice (Fig.
3.1B), suggesting that the dermonecrotic phenotype at this early time point was
independent of bacterial burden. However, by day 7 post-infection, CD36-/- mice showed
increased bacterial burden at the site of infection compared to wild-type mice, consistent
with the previously demonstrated role of CD36 in S. aureus phagocytosis (Stuart et al.,
2005). Therefore, these data suggest that CD36 plays a protective role against S. aureus
dermonecrosis and, at early time points post-infection, this protection is independent of
its role in bacterial clearance.
CD36 is a negative regulator of alpha-hemolysin mediated dermonecrosis
Hla is a secreted, pore-forming toxin which is a major contributor to dermonecrosis
during S. aureus SSSI (Inoshima et al., 2012; Kennedy et al., 2010; Kobayashi et al.,
2011b; Sampedro et al., 2014). To determine whether Hla is necessary for increased
dermonecrosis in the absence of CD36, we infected wild-type and CD36-/- mice with a
LAC isogenic hla-deletion mutant (LACΔhla) (Bubeck Wardenburg et al., 2007). At the
same inoculum used for LAC (8 x 106 CFU), mice infected with LACΔhla failed to
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develop dermonecrosis, consistent with previous reports (data not shown) (Berube et al.,
2014; Kennedy et al., 2010). However, at a higher inoculum (1.1 x107 CFU), LAChla
infected CD36-/- mice showed small, but increased abscess formation and dermonecrosis
on day three post-infection compared to wild-type mice (Fig. 3.1C, D). Notably, both
measures were significantly reduced compared to CD36-/- mice infected with LAC,
demonstrating that Hla is a major contributor to the dermonecrotic phenotype in the
knockout mice. Furthermore, mice infected with a LAC isogenic agr deletion mutant
(LACagr) (1.1 x107 CFU) did not develop dermonecrosis (Cheung et al., 2011; Daly et
al., 2015; Montgomery et al., 2010; Sully et al., 2014) (data not shown), supporting the
role of other agr-regulated factors in dermonecrosis (Cheung et al., 2011; Montgomery et
al., 2010; Wang et al., 2007b). Importantly, in contrast to infection with LAC, there was
no significant difference in day seven bacterial burden in mice infected with LACΔhla
(1.1 x107 CFU) (Fig. 3.1E). This demonstrates that CD36 is important for host clearance
of Hla-expressing S. aureus at later time points during SSSI. Together, these data
demonstrate that while CD36 largely affords protection against Hla-mediated
dermonecrosis, its protection can extend to dermonecrosis caused by other agr-regulated
virulence factors.
To confirm that the role of CD36 in limiting Hla-mediated dermonecrosis at early
time points is independent of its contribution to bacterial clearance and, based on the
results above, also independent of any potential contribution to agr regulation (Peterson
et al., 2008), we intoxicated mice by subcutaneous injection of sterile filtered supernatant
from overnight cultures (Wright et al., 2005) of LAC or LACΔhla.
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Figure 3.1 CD36-/- mice have increased dermonecrosis in response to S. aureus
infection and alpha hemolysin.
(A) Area of abscess (left), dermonecrosis (right) and (B) bacterial burden of mice
subcutaneously infected with LAC (8 x 106 CFU). N=8 mice per group from two
independent experiments. (C) Representative images of infection sites taken on day 3
post-infection (LAC, 8 x 106 CFU; LAChla 1.1 x 107 CFU) (scale bar = 5 mm). (D)
Abscess area and dermonecrosis on day 3 post-infection with LAC or LAC hla. N=8
(LAC) and 20 (LAChla) mice per group from two and four independent experiments,
respectively. (E) Bacterial burden at the site of infection 3 and 7 days post-infection with
LAChla (1.1 x 107 CFU). N=8 mice per group from two independent experiments. (F)
Mice were intoxicated by subcutaneous injection with LAC sterile supernatant (18 hour
culture). Area of abscess and dermonecrosis were measured daily. N=6 mice per group.
(G) Area of dermonecrosis of mice injected subcutaneously with 1g of purified Hla.
N=8 mice per group from two independent experiments. Data shown as mean + SEM. *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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Whereas

LACΔhla

intoxicated

mice

did

not

develop

dermonecrosis

(Supplemental Fig. 1A), CD36-/- mice intoxicated with LAC supernatant showed
significantly increased abscess size and dermonecrosis (Fig. 3.1F), compared to wild-type
controls. Furthermore, CD36-/- mice subcutaneously injected with purified recombinant
Hla (Fig. 3.1G) also showed significantly increased dermonecrosis compared to wild-type
mice, the timing of which was indistinguishable from abscess formation. As expected,
mice injected with the purified inactive HlaH35L mutant (Jursch et al., 1994) did not
develop dermonecrosis (data not shown). Together, these results confirm that CD36 is a
negative regulator of Hla-mediated dermonecrosis, independent of its role in
phagocytosis and bacterial clearance.
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Supplemental Figure 1. CD36-/- mice do not develop dermonecrosis in response to S.
aureus lacking alpha hemolysin.
(A) Area of dermonecrosis on day 1 following subcutaneous injection of mice with sterile
supernatant from the indicated strains. (B) Local il-1 transcription from experiments
shown in A. *, p<0.05; ND, not detected.
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CD36 limits inflammatory cytokine production associated with dermonecrosis
Given that Hla contributes to activation of the NLRP3 inflammasome and production
of IL-1 (Bubeck Wardenburg and Schneewind, 2008; Craven et al., 2009; MunozPlanillo et al., 2009), we predicted that the increased dermonecrosis in LAC infected
CD36-/- mice would be associated with increased local levels of IL-1 compared to wildtype controls. As expected, CD36-/- mice infected with LAC, but not with LACΔhla,
showed significantly increased local pro- and active IL-1on day 3 post-infection (Fig.
3.2A,B) compared to wild-type mice (~ increase 7.4-fold). In addition, both TNF and
CXCL1 were increased at the site of infection in LAC, but not LACΔhla, infected CD36/-

mice compared to controls (Fig. 3.2C). These results suggest that CD36 regulates

inflammatory cytokine expression in the skin of S. aureus infected mice in a Hladependent manner.
To confirm that CD36-mediated regulation of inflammatory cytokine production is
also independent of bacterial burden, we measured cytokines in the skin of mice on days
1 and 3 following intoxication with LAC sterile supernatant. As expected, local IL1TNFand CXCL1 levels increased for both mouse groups between days 1 and 3
post-intoxication. LAC intoxicated CD36-/- mice showed significantly increased local IL1expression on day 3 post-intoxication compared to wild-type controls (~ increase 3.5fold), while TNF and CXCL1 levels trended higher in the knockout mice with
differences in day 1 CXCL1 levels reaching statistical significance (Fig. 3.2D).
Additionally, local transcription of these cytokines was higher in LAC intoxicated CD36/-

versus wild-type mice, with significant increases in il-1 and cxcl1 transcription on day
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3, and in tnf transcription on day 1, post-intoxication (Fig. 3.2E). Importantly,
consistent with the lack of differential IL-1β production in LAChla infected mice (Fig.
3.2A), CD36-/- mice intoxicated with LAChla supernatant showed significantly less
local il-1 transcription on day 1 post-intoxication compared to CD36-/- mice intoxicated
with LAC supernatant (Supplemental Fig. 1B). Together, these data demonstrate that,
independent of bacterial burden, CD36 regulates IL-1 expression in the skin in response
to Hla within the S. aureus virulence secretome.
Since local IL-1 levels were elevated in both LAC infected and supernatant
intoxicated CD36-/- mice, we postulated that these mice would also show increased local
transcription of components of the NLRP3 inflammasome, including nlrp3, asc and
caspase-1 (reviewed in (Sutterwala et al., 2014)). As predicted, CD36-/- mice
subcutaneously intoxicated with LAC supernatant showed significantly increased local
nlrp3 transcription on day 3 post-intoxication compared to wild-type controls (Fig. 3.2F).
Furthermore, while there was no difference in local transcript levels of asc or capase-1
(data not shown), there was increased active caspase-1 (p10) in the skin of LAC
intoxicated CD36-/- mice compared to controls (Fig. 3.2F), indicating increased local
NLRP3 inflammasome activation in the absence of CD36.
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Figure 3.2 CD36-/- mice have increased local pro-inflammatory cytokine production
and NLRP3 inflammasome activation in response to S. aureus secreted virulence
factors.
(A-C) Mice were subcutaneously infected with LAC (8 x 106 CFU) or LAChla (1.1 x
107 CFU). The following were measured in clarified abscess tissue homogenate on day 3
post-infection: (A) IL-1, (B) Western blot for pro- and active-IL-1. (C) TNF and
CXCL1 expression. N=4-5 mice per group. (D-F) Mice were intoxicated by subcutaneous
injection with LAC sterile supernatant (18 hour culture) and the following measured in
injection site tissue homogenate on days 1 and 3 post-intoxication:(D) Cytokine
expression and (E) il-1b, tnf and cxcl1 transcription. (F) nlrp3 transcription and caspase1 expression and activation (Western blot), in LAC intoxicated mice on day 3 postintoxication. N=4-8 mice per group. Data reported as mean + SEM. ns, not significant; *,
p<0.05; **, p<0.01; ***, p<0.001.
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CD36 regulates neutrophil accumulation driven by S. aureus secreted virulence
factors

Neutrophil-derived IL-1 is sufficient for abscess formation during S. aureus SSSI,
and neutrophils have been shown to produce IL-

(Cho et al.,

2012b). Therefore, we predicted that the increased dermonecrosis and ILin LAC supernatant-intoxicated CD36-/- mice would be associated with increased local
neutrophil accumulation. To address this, we subcutaneously intoxicated mice with LAC
supernatant and prepared single cell suspensions of injection site tissue on day 1 postintoxication. As predicted, CD36-/- mice had significantly increased neutrophil (Ly6G+)
accumulation at the site of intoxication compared to wild-type mice (Fig. 3.3A,B).
Furthermore, although the total number of cells present did not differ, CD36-/- mice had
fewer macrophages (F4/80+) at the site of intoxication, compared to controls (Fig.
3.3C,D). Importantly, to our knowledge, no deficiencies in macrophage levels in CD36-/mice have been reported. Therefore, these data suggest a role for CD36 in regulating
immune cell accumulation in the skin in response to S. aureus secreted virulence factors.
To begin to address the mechanism of increased dermonecrosis, immune cell
accumulation and IL-1 production in the skin of LAC intoxicated CD36-/- mice, we first
asked whether neutrophils from CD36-/- mice produced increased ILHla, compared to neutrophils from wild-type controls. Using flow cytometry, we were
unable to detect CD36 on neutrophils isolated from wild-type mice (data not shown),
suggesting that the presence or absence of this protein on neutrophils themselves did not
contribute to the dermonecrotic phenotype in CD36-/- mice.
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Figure 3.3. CD36-/- mice have increased local neutrophil accumulation compared to
wild-type mice following LAC supernatant injection.
Flow cytometry analysis of single cells suspensions from injection site tissue on day 1
post-LAC intoxication of C57BL6 and CD36-/- mice. (A,B) Presence of Ly6G+ cells, (C)
total cell count and (D) F4/80+ cells at the site of intoxication. N=6 mice per group from
two independent experiments. (E) il-1b and nlrp3 transcription and (F) IL-1 expression
by bone marrow derived neutrophils in response to 1 h incubation with LAC sterile
supernatant or media control. N=6 from two independent experiments. (G) Day 1
dermonecrosis, (H) along with MPO and local IL-1 levels, from supernatant intoxicated
CD36-/- mice following treatment with anti-Ly6G or isotype control. Values are expressed
as percent of isotype control. N=12-15 mice/group from four independent experiments.
Data are mean ± SEM. ns, not significant; *, p<0.05; **, p<0.01.
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In addition, bone marrow-derived neutrophils from wild-type and CD36-/- mice
showed similar il-1and nlrp3 transcription, and IL-1 production, upon exposure to
LAC supernatant (Fig. 3.3E,F). Therefore, these results point to a mechanism whereby
CD36 negatively regulates dermonecrosis and IL-1 production in the skin by controlling
neutrophil accumulation in response to S. aureus secreted virulence factors, rather than
by directly affecting the neutrophil response to Hla.
If neutrophil accumulation at the site of S. aureus intoxication is responsible for the
increased dermonecrosis in CD36-/- mice, then depletion of neutrophils prior to
intoxication should prevent the enhanced dermonecrotic phenotype. As expected, on day
1 post-intoxication, CD36-/- mice treated with antibody targeting Ly6G to deplete
neutrophils, showed significantly reduced dermonecrosis, local IL-1 production and
local myeloperoxidase (MPO) levels, a surrogate for neutrophil accumulation (Cho et al.,
2012b), compared to isotype treated controls (Fig. 3.3G).

Together, these data

demonstrate that CD36 protects against neutrophil-dependent skin injury induced by S.
aureus secreted virulence factors.
We next asked whether increased dermonecrosis and neutrophil accumulation in
CD36-/- mice resulted from increased neutrophil influx. Maximum neutrophil
accumulation in the developing lesion has been reported to occur at six hours following
S. aureus infection (Ford et al., 1989; Wright et al., 2005). Therefore, we assessed local
MPO levels, as an indicator of neutrophil accumulation, along with IL-1β, TNF and
CXCL1 levels at six hours following LAC infection of wild-type and CD36-/- mice. At
this time point, there was no significant difference in MPO, IL-1β, TNF or CXCL1
expression at the site intoxication between the two mouse groups (Supplement Fig. 2),
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suggesting that differences in neutrophil accumulation in the absence of CD36 do not
result from increased neutrophil influx early post-infection.
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Supplemental Figure 2. Local inflammation hours post intoxication.
6
Mice were infected with LAC (8 x 10 CFU) and tissues collected at six hours postinfection. (A) MPO, (B) IL-1, TNF and CXCL1 levels at the site of infection.
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Macrophage CD36 is sufficient to limit dermonecrosis in CD36-/- mice
CD36 on macrophages facilitates clearance of apoptotic neutrophils, thus limiting
tissue damage which follows loss of membrane integrity in dying cells and the
subsequent release of noxious cell contents (Navazo et al., 1996; Ren et al., 1995; Savill
et al., 1991; Savill et al., 1992; Weiss, 1989). If CD36 on macrophages is necessary to
limit tissue damage caused by S. aureus secreted virulence factors, then administration of
macrophages from wild-type (CD36+/+) mice, but not from CD36-/- mice, should prevent
the excessive dermonecrotic phenotype in CD36-/- mice following S. aureus intoxication.
As expected, compared to untreated CD36-/- mice, local subcutaneous administration of
wild-type macrophages to CD36-/- mice four hours post-intoxication was sufficient to
significantly reduce day one dermonecrosis, whereas administration of macrophages from
CD36-/- mice had no effect (Fig. 3.4A). Administration of CD36+/+ macrophages to
CD36-/- mice also reduced local IL-1and myeloperoxidase (MPO) levels (Fig. 3.4B).
Furthermore, administration of CD36+/+, but not CD36-/-, macrophages to wild-type mice
prevented dermonecrosis, with further reductions in local IL-1and MPO levels (Fig.
3.4A,B). Therefore, the ability to prevent excessive dermonecrosis in the CD36-/- mice by
administration of CD36+/+, but not the same number of CD36-/- macrophages, suggests
that the protective mechanism of action is dependent on the presence of CD36 on the
macrophages after reaching the site of inflammation.
To determine whether inhibition of dermonecrosis by administration of CD36+/+
macrophages is associated with a local reduction in dying neutrophils, we used propidium
iodide staining (Nygaard et al., 2012) to assess the loss of membrane integrity in
neutrophils isolated from the site of intoxication. As expected, neutrophils isolated from
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the site of intoxication of CD36-/- mice showed reduced propidium iodide (PI) staining
following CD36+/+ macrophage treatment compared to untreated controls (Fig 3.4C,D).
Furthermore the reduction in PI uptake was reversed by pre-incubating macrophages with
cytochalasin to inhibit phagocytosis, consistent with the previously described role of
CD36 in macrophage phagocytosis and clearance of apoptotic neutrophils (Navazo et al.,
1996; Ren et al., 1995; Savill et al., 1991; Savill et al., 1992). Together, these data
demonstrate that CD36 expression on macrophages is necessary to limit skin injury
associated with inappropriate neutrophil accumulation in response S. aureus secreted
virulence factors, and suggest that the mechanism of action is via CD36-mediated
phagocytosis and clearance of apoptotic neutrophils.
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Figure 3.4 CD36+/+ macrophages negatively regulate the dermonecrotic phenotype
of LAC intoxicated CD36-/- mice.
Mice were intoxicated by subcutaneous injection with LAC sterile supernatant. 4 h later,
mice were either left untreated or peritoneal macrophages were injected adjacent to the
site of intoxication. (A) Area of dermonecrosis and local (B) IL-1β and MPO levels
measured day 1 post-intoxication. Data reported as mean+ SEM. N=4-6 mice per group
from two independent experiments. (C,D) Membrane integrity of Ly6G+ cells from
intoxication site skin sections measured by flow cytometry as percent propidium iodide
uptake relative to CD36-/- controls. N=3-4 mice/group. ns, not significant; ND, not
detected; *, p<0.05; **, p<0.01; ***, p<0.001.
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Discussion
Host innate defense against S. aureus skin infections is a highly orchestrated process
aimed at clearing the infection and minimizing tissue damage. If left unchecked,
however, the innate immune response to S. aureus infection, and to virulence factors such
as Hla, can itself contribute to tissue injury. Here we report that CD36, a scavenger
receptor that facilitates macrophage clearance of apoptotic neutrophils (Navazo et al.,
1996; Ren et al., 1995; Savill et al., 1991; Savill et al., 1992), plays a major role in
regulating Hla-mediated skin injury. In the absence of CD36, neutrophils recruited to the
skin, in large part by Hla (Bartlett et al., 2008), can accumulate, become necrotic and
ultimately cause tissue damage likely due to the release of their toxic cellular contents.
Importantly, the administration of CD36-bearing macrophages is sufficient to limit
dermonecrosis in mice lacking CD36, and to prevent dermonecrosis in wild-type mice.
CD36+/+

macrophage

administration

significantly

reduces

necrotic

neutrophil

accumulation at the site of intoxication, a benefit which is negated by obstructing
macrophage actin polymerization. Therefore, these data support a mechanism of action
whereby CD36-mediated macrophage phagocytosis of apoptotic neutrophils plays a
significant role in host regulation of Hla-mediated dermonecrosis. Although further
research is needed, these results may suggest that therapies targeted at local upregulation
of CD36 on macrophages could prove efficacious in ameliorating S. aureus-mediated
skin injury.
The formation of neutrophil-rich abscesses is considered a host defense mechanism
for preventing bacterial dissemination and pathogenesis in response to S. aureus skin
infection. However, this innate neutrophil response must be tightly controlled to limit
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self-damage to host tissues. The potential damage resulting from unregulated neutrophil
accumulation is suggested by the following: (i) neutrophils produce IL-1 to propagate
their own recruitment (Cho et al., 2012b; Miller et al., 2006; Miller et al., 2007), (ii) they
are short-lived and subject to lysis by S. aureus-secreted virulence factors (Alonzo and
Torres, 2013; Rigby and DeLeo, 2012; Surewaard et al., 2013), and (iii) necrotic
neutrophils release toxic substances, such as proteases and elastase (Henson and
Johnston, 1987), as well as DAMPS (danger-associated molecular patterns) such as Highmobility group box 1 protein (HMGB1) (Raucci et al., 2007), which all contribute to
tissue damage. Here we report that CD36 contributes to regulation of the host innate
response to virulence factors secreted by S. aureus by limiting accumulation of dead or
dying neutrophils during SSSI. It is important to note that, in addition to having more
neutrophils at the site of inflammation compared to controls, S. aureus intoxicated CD36/-

mice also had fewer macrophages, suggesting a potential role for CD36 in macrophage

accumulation in this model. However, local administration of CD36+/+, but not an
equivalent number of CD36-/- macrophages, prevented the enhanced dermonecrotic
phenotype of CD36-/- mice. Therefore, the primary role of CD36 in regulating the host
innate response in this model is in preventing excessive neutrophil accumulation once
macrophages are at the site of infection or intoxication.
CD36 is a multifunctional protein with numerous and diverse ligands, co-receptors and
functions (Park, 2014; Silverstein and Febbraio, 2009). Whether the downstream effects
of CD36 signaling are pro- or anti-inflammatory depend on the nature of the ligand and
the accompanying co-receptors. CD36 was first classified as a scavenger receptor and
best studied for its role in sterile inflammation and atherosclerosis. In conjunction with
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TLR4 and TLR6, CD36-mediated uptake of oxidized low density lipoprotein (oxLDL)
results in the formation of intracellular cholesterol crystals, which drive activation of the
NLRP3 inflammasome and secretion of the pro-inflammatory cytokine IL-1 (Sheedy et
al., 2013; Stewart et al., 2010). This in turn leads to foam cell formation and
atherosclerosis (reviewed in (Park, 2014)). CD36 also contributes to the host
inflammatory response to Gram-positive pathogens. In this respect, CD36 mediates
production of reactive oxygen species in response to Propionibacterium acnes (Grange et
al., 2009), phagocytosis of S. aureus (Stuart et al., 2005), and, together with TLR2,
recognition of S. aureus cell wall components (Hoebe et al., 2005a). Importantly, each of
these functions results in a pro-inflammatory cytokine response (Grange et al., 2009;
Hoebe et al., 2005a; Stuart et al., 2005). In contrast, CD36 suppresses early proinflammatory cytokine production by both macrophages and epithelial cells in response
to lipotechoic acid-phosphocholine complexes from Streptococcus pneumoniae (Sharif et
al., 2013). Our findings extend the known anti-inflammatory contributions of CD36 to
protection against Hla-mediated S. aureus dermonecrosis, and suggest that therapeutic
modulation of CD36 expression during skin infection could both enhance bacterial
clearance (Stuart et al., 2005) and limit tissue damage caused by the host response to S.
aureus virulence factors.
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Abstract
Staphylococcus aureus is the primary cause of skin and soft tissue infections
(SSTIs) in the USA. Between January 2013 and June 2015 at the University of New
Mexico Hospital, almost twice as many males were diagnosed with S. aureus SSTI
compared to females. Males and females differ in susceptibility to infection by various
pathogens, with males frequently showing increased susceptibility and morbidity.
However, the contributions of innate differences in the physiological response to
infection, versus behavioral differences, to this bias remain largely unexplored. We
hypothesized that estrogen mediates protection against S. aureus SSTI by increasing
bacterial clearance leading to reduced pathogenesis. Here we show that male mice are
more susceptible to S. aureus skin infection as evidenced by reduced bacterial clearance
and increased inflammation compared to female mice. Furthermore, ovariectomized mice
had reduced bacterial clearance compared to sham control surgery mice, further
indicating the importance of estrogen in controlling S. aureus clearance. Importantly,
estrogen treated macrophages were better able to phagocytize and kill S. aureus, and had
reduced pro-inflammatory cytokine production, compared to vehicle-treated controls.
Together, these data demonstrate that estrogen positively regulates host innate defense
against S. aureus SSTI.
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Introduction
Recognizing that sex is a major contributor to disease susceptibility, the National
Institutes of Health (NIH) recently enacted a policy (NOT-OD-15-102) that NIH-funded
basic biomedical research must be conducted in both male and female animals, and the
resulting data stratified in order to expose sex differences in disease. However, sex has
long been recognized as an important variable in susceptibility to infectious disease, and
epidemiological studies show that males are at an increased risk of many bacterial
infections compared to females (McClelland and Smith, 2011; Silva, 2011). However, it
is largely unclear if increased infection rates in males are due to sex differences in
behavior, such as handwashing (Johnson et al., 2003), or to innate physiological
differences between the sexes, such as hormones, or a combination thereof (Klein, 2000).
Staphylococcus aureus is the dominant cause of skin and soft tissue infections (SSTI)
presenting to emergency departments throughout the US (Moran et al., 2006; Talan et al.,
2011). Although clinical reports indicate that males more often present with impetigo,
caused by S. aureus (Kim et al., 2011), as well as methicillin-resistant S. aureus (MRSA)
blood stream infections (Savill et al., 1989), compared to females, the potential for sex
bias in S. aureus SSTI has not been directly assessed. However, related studies suggest
that females would be innately protected. For example, in an artificial implant infection
model, female rabbits showed increased survival following infection with S. aureus
(Best et al., 1984), and the protective effect was lost with ovariectomy (Best et al., 1984).
Additionally, estradiol as shown to reduce pathogenesis in a mouse model of S. aureus
induced arthritis (Gjertsson et al., 2012), and alveolar macrophages from female versus
male mice were shown to be better able to kill internalized S. aureus (Yang et al., 2014).
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However, whether estrogen protects against S. aureus skin infection has not been
investigated.
Here we utilized a murine model of S. aureus dermonecrosis to test the hypothesis
that estrogen mediates protection against S. aureus SSTI by increasing bacterial clearance
and reducing pathogenesis. As expected, female mice showed reduced dermonecrosis and
increased bacterial clearance over the course of a seven day infection compared to male
controls. The female protective advantage against S. aureus skin infection was observed
in two strains of mice, C57BL/6 and BALB/c, suggesting that protection is independent
of genetic background. Additionally, ovariectomized mice demonstrated a reduction in
bacterial clearance compared to sham surgery control mice, indicating the importance of
estrogen producing ovaries for bacterial clearance. Importantly, compared to vehicle
treated control cells, treatment of a male mouse macrophage cell line (Raw 264.7 cells)
with increasing concentrations of 17β-estradiol (E2) significantly increased both
phagocytosis and intracellular killing of S. aureus. Therefore, these data suggest that
estrogen positively regulates host innate defense against S. aureus SSTI
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Materials and Methods

Bacterial growth conditions
The strain used for these studies, S. aureus USA300 LAC, was provided by Dr. Frank
DeLeo (NIH/NIAID) and was grown in trypticase soy broth (TSB) at 37°C to early
exponential phase (previously described) (Rothfork et al., 2004).

Bacterial colony

forming units (CFUs) were determined by plating serial dilutions on sheep blood agar
(Becton Dickinson, Franklin Lakes, NJ).

Mouse model of S. aureus skin and soft tissue infection
The animal work in this study was approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of New Mexico and was carried out at the
AAALAC accredited Animal Research Facility of the University of New Mexico Health
Sciences Center in strict accordance with recommendations in the Eighth Edition of The
Guide for the Care and Use of Laboratory Animals and the USA Animal Welfare Act.
C57BL/6 and BALB/c mice were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice used in these studies were age and size matched (8-12 weeks, 22-28 g). The
mouse model of S. aureus skin infection was performed as previously described
(Malachowa et al., 2013).

In brief, twenty-four hours before infection, mice were

anesthetized by isoflurane and hair was removed from the right flank using Nair (Church
7

CFUs

of LAC was injected subcutaneously into the right flank of anesthetized mice. Mice were
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weighed daily as a marker of systemic morbidity, and photographed for abscess and
dermonecrosis area, which was measured using ImageJ analysis (Schneider et al., 2012).
Tissue collection
On day 3 or day 7 post-infection, mice were sacrificed by CO2 asphyxiation. Skin
abscesses (area = 2.25 cm2) were collected for CFU determinations or cytokine
measurements. To determine CFUs, abscesses were collected in bead-beating tubes
containing 2.3 mm Zirconia/Silica beads (BioSpec Products Inc., OK) and 1 mL of
HBSS- (Gibco, Grand Island, NY) with 0.2% Human serum albumin (Sigma, St. Louis,
MO). Tissue was disrupted for 3 min in 1 min intervals using a Mini-Bead Beater-24
(BioSpec Products Inc., OK). Homogenates were diluted into PBS containing 0.1%
Triton X-100 and sonicated. This was followed by plating serial dilutions on blood agar
to enumerate CFUs. For cytokine analyses, abscess homogenates were clarified by
centrifugation at 12,500 x g and supernatant was stored at -80°C until use.

Quantification of cytokines
Cytokines were measured in clarified supernatant from homogenized abscesses using
custom designed multiplex assays (Millipore, Billerica, MA) according to the
manufacturer’s directions.

Macrophage phagocytosis and killing of S. aureus
Raw 264.7 cells were grown in Dulbecco’s Modified Eagle’s Medium with 10% FBS,
10mM Hepes, 2mM L-glutamine, 100U/mL penicillin and 100ug/mL streptomycin at
37°C in 5% CO2. Twenty-four hours prior to the assay, cells were washed with PBS and
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the medium replaced with DMEM with 10mM Hepes, 2mM L-glutamine, 100U/mL
penicillin and 100ug/mL streptomycin and 10% Charcoal stripped FBS (to limit cell
exposure to hormones) (JR Scientific, Woodland, CA).

Prior to the assay, early

exponential-phase LAC was cultured in 3 ml of TSB at 2x107 CFU/ml with 50 nM
exogenous AIP1 (Biopeptide Co., San Diego, CA) at 37°C while shaking for 5 hours.
The bacteria were centrifuged, washed in PBS, sonicated, and suspended at 2x108
CFUs/mL in DMEM with 10% Charcoal stripped FBS. The bacteria were opsonized
overnight with rabbit anti- S. aureus IgG at 100 ug/ml (Accurate Chemical & Scientific
Co., Westbury, NY) at 4°C on ice. On the day of the assay, RAW 264.7 cells were
detached with Cell Stripper (Corning, Manassas, VA), and enumerated using the TC 20
Automated Cell Counter (Bio-rad). Cell were resuspended at 2x107 cells/ml in DMEM
with 10% Charcoal stripped FBS and incubated with 500nM 17-β Estradiol or 5µM 17-β
Estradiol (Sigma-Aldrich, St. Louis, MO) or vehicle control for 2 hours at 37°C in 5%
CO2. The cells were then combined with opsonized bacteria at a multiplicity of infection
(MOI) of 10. The cells and bacteria were centrifuged at 500 x g for 3 min to initiate
contact, followed by incubation at 37°C in 5% CO2 for 1 hour to allow for phagocytosis.
At 1 hour, lysostaphin (Sigma-Aldrich) was added at 2ug/ml for 15 min to kill
extracellular bacteria and then removed by centrifugation and replaced with fresh
medium. Half of the samples were immediately processed for CFU determination to
determine percent phagocytosis relative to initial bacteria concentration, and the other
half were incubated for an additional 4 hours at 37°C in 5% CO2 before CFU
enumeration to determine percent killing. Bacteria were enumerated by dilution into PBS
with 0.1% Triton X-100, followed by sonication and plating onto blood agar.
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Statistical analysis
Statistical analyses were performed using Prism 6.0 software (Graph Pad Software, Inc.,
La Jolla, CA). In vitro data were analyzed by Student’s t test and in vivo results by the
Mann-Whitney U test for non-parametric data.
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Results
Females are diagnosed with S. aureus skin infection at UNM Hospital less frequently
than males

To determine if males have increased rates of S. aureus skin infections compared to
females locally, we queried the UNM Clinical and Translation Science Center (CTSC)
Informatics Integrating Biology and the Bedside (i2b2) Database. The database was
searched for patients that were seen between 1/1/2013 and 6/30/15, and were of childbearing age (18-44), and had a diagnosis of either MSSA or MRSA skin infection. Of 84
patients diagnosed with an MSSA skin infection, 60 (71.43%) were male and 24
(28.57%) were female (Fig. 4.1).

Of 176 patients diagnosed with an MRSA skin

infection, 106 (60.23%) were male and 70 (39.77%) were female (Fig. 4.1). Although
this is a limited group of patients, this epidemiological data suggests that males are more
likely to develop clinical S. aureus skin infections than females.
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Figure 4.1 More males present to the UNM Hospital with MRSA or MSSA skin
infections than females.
CTSC i2b2 Database was queried for patients that were seen between 1/1/2013 and
6/30/15, and were in the age range of 18-44, with a diagnosis of MSSA (N=84) or MRSA
(N=176) skin infection. Data are shown as percent of total stratified by sex.
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Female mice are less susceptible to S. aureus skin infections compared to males
To begin to address whether physiological factors contribute to the sex bias observed
in human male susceptibility to S. aureus SSTI, we used a well-established mouse model
of S. aureus skin infection (Malachowa et al., 2013). Specifically, we infected C57BL/6
male and female mice by subcutaneous injection with MRSA USA300 LAC. Compared
to male mice, female mice had significantly smaller abscesses and reduced dermonecrosis
on days 1-7 post-infection (Fig. 4.2A-E). At the apex of dermonecrosis on day 3 postinfection, there was a slight, but non-significant reduction in bacterial burden in female
versus male mice (Fig. 4.2F), suggesting that differences in inflammatory response,
rather than bacterial clearance, largely contributed to disease severity in males at this
early time point. However, by day 7 post-infection, female mice showed significantly
reduced bacterial burden at the site of infection compared to males. Therefore, these data
demonstrate that, compared to males, C57BL/6 female mice are innately able to limit S.
aureus SSTI.
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Figure 4.2 Male C57BL/6 mice have increased dermonecrosis and reduced bacterial
clearance compared to female C57BL/6 mice during S. aureus infection.
C57BL/6 male and female mice were infected subcutaneously with S. aureus USA 300
LAC. (A) Representative images of the site of infection on day 3 post-infection. (B)
Abscess area measured daily. (C) Quantification of area under the curve for abscess size
over the course of infection. (D) Dermonecrosis measured daily. (E) Quantification of
area under the curve for dermonecrosis formation over the course of infection. (F)
Bacterial burden at the site of infection on days 3 and 7 post-infection. N=8 mice/group
from two independent experiments. Data shown as mean + SEM. *p< 0.05, ** p< 0.01,
*** p< 0.001.
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To verify that female protection against S. aureus skin infections is not limited to a
single murine genetic background, we repeated these studies in BALB/c male and female
mice. Again, female mice had significantly smaller abscesses and reduced dermonecrosis
on days 1-3 post-infection compared to males (Fig. 4.3A-C). Female BALB/c mice
showed a significant reduction in local bacterial burden compared to males on day 3
post-infection (Fig. 4.3D). These data suggest that the sex bias in susceptibility to S.
aureus skin infection is independent of murine genetic background.
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Figure 4.3 Male BALB/c mice have increased dermonecrosis and reduced bacterial
clearance compared to female mice during S. aureus skin infection.
BALB/c male and female mice were infected subcutaneously with S. aureus USA 300
LAC. (A) Representative images of the site of infection on day 3 post-infection. (B)
Abscess area and (C) dermonecrosis were measured daily. (D) Bacterial burden at the site
of infection on day 3 post-infection. N=8 mice/group from two independent experiments.
Data shown as mean + SEM. *p< 0.05, ** p< 0.01, *** p< 0.001.
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Female mice have reduced local inflammatory cytokine expression during S. aureus
skin infection compared to male mice

Given that host innate immune cells produce local cytokines during S. aureus skin
infection (Krishna and Miller, 2012b), we predicted that the reduced dermonecrosis in
MRSA infected female mice would be associated with reduced local levels of
inflammatory cytokines compared to male mice. As expected, although baseline cytokine
levels in skin from uninfected mice did not differ between the groups (data not shown),
female mice showed significantly decreased local production of IL-1L-6, TNF-α and
CXCL1 on day 3 post-infection compared to males in both C57BL/6 Fig. 4.4A) and
BALB/c mice (Fig. 4.4B). Together, these data support a mechanism whereby females
may limit S. aureus SSTI, at least in part, through strict regulation of the skin
inflammatory response.
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Figure 4.4 Male mice have increased local pro-inflammatory cytokine production
during S. aureus skin infection compared to females.
(A) C57BL/6 male and female mice were infected subcutaneously with S. aureus USA
300 LAC. The following were measured in clarified abscess homogenate on day 3 postinfection: IL-1β, IL-6, TNF-α, CXCL1. (B) BALB/c male and female mice were infected
subcutaneously with S. aureus USA 300 LAC. The following were measured in clarified
abscess homogenate on day 3 post-infection: IL-1β, IL-6, TNF-α, CXCL1. N=8
mice/group from two independent experiments. Data shown as mean + SEM. *p< 0.05,
** p< 0.01, *** p< 0.001.
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Estrogen facilitates S. aureus clearance in vivo and in vitro
To more directly test whether estrogen mediates protection against S. aureus SSTI
by increasing bacterial clearance, we infected ovariectomized and sham surgery control
female mice by subcutaneous injection with LAC. Compared to sham surgery controls,
ovariectomized mice had reduced clearance of bacteria at the site of infection (Fig. 4.5AB), supporting a mechanism whereby estrogen is a positive regulator of host innate
defense against S. aureus skin infection.
To ascertain whether estrogen treatment could enhance S. aureus clearance by
innate immune cells, we treated Raw 264.7 murine macrophages with 17β-Estradiol (E2)
or vehicle, followed by incubation with S. aureus. Compared to vehicle-treated controls,
estradiol treated macrophages demonstrated increased phagocytosis and killing of S.
aureus (Fig. 4.5C). Additionally, estradiol treated macrophages produced less IL-6,
TNF-α, and CXCL1 compared to vehicle- treated cells (Fig. 4.5E-G), consistent with our
in vivo observations (Fig. 4.4). To verify that enhanced bacterial killing with estradiol
treatment was dependent on the macrophages, rather than possible antimicrobial effects
of estradiol on S. aureus, we incubated S. aureus with estradiol and observed no direct
killing (Fig. 4.5D). Therefore, these results support our hypothesis that estrogen mediates
protection against S. aureus SSTI by increasing bacterial clearance and reducing
pathogenesis.
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Figure 4.5 Ovariectomized mice have reduced bacterial clearance and 17β-Estradiol
causes an increase in phagocytosis and killing of S. aureus by Raw 264.7 cells.
Ovariectomized and sham surgery control C57BL/6 female mice were infected
subcutaneously with S. aureus USA 300 LAC. (A) Representative images of infection
site, and (B) bacterial burden at the site of infection on day 3 post-infection. N=8
mice/group from two independent experiments. (C, E-G) Raw 264.7 macrophages were
incubated for 2 hours with either vehicle control or 500nM E2 or 5M E2, followed by
incubation with opsonized S. aureus. (C) Percent of intracellular bacteria at 1 hour and 5
hours compared to starting CFUs. Percent of S. aureus killed at 5 hours, compared to
bacteria phagocytosed by 1 hour. (D) CFUs of estradiol treated S. aureus. (E-G)
Cytokines produced by Raw 264.7 cells measured at 5 hours post incubation with S.
aureus. N=6 per group. Data shown as mean + SEM. Ns, not significant; *p< 0.05, ** p<
0.01, *** p< 0.001.
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Discussion
Host innate defense against S. aureus skin infections is a highly orchestrated process
aimed at clearing the infection, thereby reducing pathogenesis. Here we report that
estrogen plays a protective role against S. aureus skin infections. Our data demonstrate
that female mice are less susceptible to S. aureus SSTI compared to male mice, as
indicated by reduced abscess and dermonecrosis development, and female mice have
increased bacterial clearance during infections compared to males.

Raw 264.7

macrophages treated with estradiol are better able to phagocytose and kill S. aureus
compared to vehicle control treated cells, supporting an estrogen dependent mechanism
of host protection.

Therefore, these data support a mechanism of action whereby

estrogen promotes clearance of S. aureus. Furthermore, our data demonstrate that the
epidemiological differences in S. aureus SSTI in males and females may be attributed, at
least in part, to the innate physiological difference of the presence of the sex hormone
estrogen.
Understanding the sex bias in susceptibility to S. aureus skin infections may aid in
developing treatments to reduce pathogenesis and enhance bacterial clearance. Although
further studies are needed, our data suggest that estrogen could have therapeutic potential
to combat S. aureus skin infection. Determination of the specific targets for estrogenmediated enhancement of the immune response to S. aureus could facilitate therapeutic
development. At present, the role of the three estrogen receptors ERα, ERβ, and GPER
in host innate defense against S. aureus undefined. However, many estrogen receptor
specific synthetic agonists and antagonists are readily available, as well as, specific
estrogen receptor knock out mice, to delineate relevant paths important for defense
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against S. aureus. Activation of the appropriate estrogen receptor(s) could provide a
therapeutic target to initialize the important anti-bacterial signaling pathways used in the
innate immune response against S. aureus skin infection. Should estrogen be viable as a
therapeutic against S. aureus, there could foreseeably be resistance to systemic
administration of estrogen. In order to combat that, and prevent off-target effects, we
propose that formulations of specific agonists against an estrogen receptor(s) targeted at
the site of infection could prove efficacious in ameliorating S. aureus-mediated skin
injury. Clinical utilization of these specific agonists via topical application may bolster
the innate immune response against S. aureus skin infection.
The NIH officially recognized the importance of including sex as a potential variable
in basic biomedical research, and released a policy stating that federally funded studies
need to be conducted in cells or whole animal from both sexes. In support of this, our
studies demonstrate that sex is a significant variable in susceptibility to S. aureus SSTI.
The significance of the differing immune response between males and females to this
clinically important pathogen suggests that limiting research to a single sex may bias
research results and potentially negatively impact outcomes of clinical trials based on
these studies. Therefore, future studies testing potential therapeutics or vaccines against
S. aureus skin infections need to take into consideration the differing immune response
between males and females in order to determine the best method of treatment.
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Chapter 5 Summary, Future Directions, and Conclusions
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Summary
S. aureus is an important clinical pathogen as it is the dominant cause of skin and
soft tissue infections (SSTIs) (Moran GJ and LK, 2006), which in the USA account for
11.6 million outpatient and emergency room visits, as well as ~500,000 hospital
admissions per year (McCaig et al., 2006). The emergence of antibiotic resistant S.
aureus over the last few decades and the widespread identification of methicillin-resistant
S. aureus (MRSA) isolates highlight the dangers of infection with this bacterial pathogen.
In a recent report, 76% of bacterial skin infections presenting to the emergency room
were due to S. aureus infection, and of those, 78% were caused by MRSA (Moran GJ and
LK, 2006). MRSA has been labeled a serious threat by the CDC due to its harmful
impact on public health (CDC, 2013). MRSA infections are associated with increased
mortality rates, longer hospitals stays and increased financial burden, compared to
infections caused by methicillin-sensitive S. aureus (MSSA) (Lodise and McKinnon,
2007). Even more concerning, a significant proportion of MRSA infections are due to
community-acquired strains (CA-MRSA), which can cause deadly disease in otherwise
healthy individuals (Otto, 2013). From this epidemiological data, it is clear that S. aureus
is a deadly pathogen responsible for a major burden on the health care system.
With the continued development of antibiotic resistance, and lack of a functional
vaccine to prevent S. aureus infection, it becomes imperative to better understand the
mechanisms of host defense against this pathogen in the hope of developing therapeutics
to bolster host immunity. Furthermore, understanding how the protective innate immune
response to S. aureus skin infection occurs could aid in development of prophylactic
strategies to prevent infection. It is especially important to understand the mechanisms of
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the host immune response to S. aureus for patient populations that are at risk for more
serious forms of the disease or repeated infections, such as surgical patients, diabetics,
and the immunocompromised.
In Chapter 3, we examined the role of the scavenger receptor CD36 in combating
skin infections caused by S. aureus. Before these studies were conducted, it was unclear
how the host limited inflammation during infection, because host detection of the S.
aureus secreted pore-forming toxin alpha hemolysin (Hla) leads to an intense production
of pro-inflammatory cytokines and the recruitment of the main responders, neutrophils
(Kobayashi et al., 2015). If left unchecked or unregulated, the inflammatory response
could cause collateral damage to healthy tissue due to neutrophil necrosis, which is the
release of noxious components from azurophilic granules and DAMPs during neutrophil
death, if the cells are not cleared by macrophages via phagocytosis (Savill et al., 1992). It
was also not known if CD36 played a role in controlling the inflammatory response to S.
aureus. Therefore, we postulated that the scavenger receptor CD36, which facilitates
macrophage clearance of apoptotic neutrophils, would play a significant role in regulating
local inflammation and dermonecrosis mediated by Hla. In Chapter 3, we identified a
novel role for CD36 during S. aureus skin infection.

We found that CD36 on

macrophages is essential to regulation of the host innate immune response to S. aureus
Hla-dependent invasive skin infection through its ability to recognize and direct
macrophage phagocytosis of dying neutrophils.

This work illuminates how CD36

functions to limit inflammation and clear dying neutrophils at the site of infection,
preventing excessive Hla-mediated damage to surrounding healthy tissue during
infection. Importantly, this innate effector role of CD36 is independent of its previously
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reported role in bacterial phagocytosis (Hoebe et al., 2005b; Stuart et al., 2005). Taken
together, the work in Chapter 3 significantly expands our understanding of the
contribution of scavenger receptor CD36, best known for its role in atherosclerosis (Park,
2014; Silverstein, 2009), to host innate defense against S. aureus skin infection,
specifically through regulation of the host inflammatory response. Furthermore, our
work suggests that the role of CD36 in regulation of the skin inflammatory response may
extend to other skin infections and dermatological conditions which cause dermonecrosis.
In Chapter 4, we examined sex bias during skin infection with S. aureus. Clinical
reports indicate that males more often present with impetigo, a rash-like contagious
infection (Kim et al., 2011), and blood stream infections caused by MRSA (Savill et al.,
1989) compared to females. We queried the UNM CTSC database and found that
between January 2013 and June 2015 at the University of New Mexico Hospital, almost
twice as many males were diagnosed with S. aureus skin infections compared to females.
However, the potential for sex bias in S. aureus skin infection has not been directly
assessed. It is unknown if males presented with skin infections more often than females
due to behavioral differences, such as occupation and hygiene (Collins and O'Connell,
2012; Johnson et al., 2003), innate physiological differences, such as sex hormones
controlling signaling pathways, or a combination of the two components. Therefore, we
postulated that estrogen, (Bernin and Lotter, 2014; McClelland and Smith, 2011),
mediates protection against S. aureus skin infections by increasing bacterial clearance
and reducing pathogenesis. We showed for the first time that female mice have innate
resistance to S. aureus skin infection, therefore suggesting that physiological differences
are a major contribution to sex bias susceptibility to S. aureus. Furthermore, we found
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that estrogen enhanced macrophage phagocytosis and clearance of S. aureus, providing a
potential mechanism by which estrogen limits pathogenesis during skin infection.
Importantly, the studies in Chapter 4 support a biological basis for reduced clinical
presentation of S. aureus skin infection in females compared to males, and may have
clinical implications for treatment based on sex. This work further suggests that estrogen
may be protective against other bacterial pathogens, and highlights the importance of
considering sex bias in pre-clinical studies, a variable that is often overlooked in
biomedical research.
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Future Directions
Although in Chapter 3 we determined that CD36 is essential for regulation of the
host innate immune response to S. aureus dermonecrosis mediated by Hla, and in Chapter
4 that sex bias during S. aureus skin infections is due, at least in part, to the functions of
estrogen, many questions still remain from these studies. For the work completed in
Chapter 3, the gaps in knowledge that still remain to be addressed include i) whether
upregulation of CD36 using PPARγ agonists has therapeutic potential, ii) whether
reduced CD36 expression in chronic granulomatous disease patients increases
susceptibility to S. aureus, iii) whether soluble CD36 has a role in diabetic patients
susceptibility to infection, and iv) whether administration of peptides from commensals
that signal through CD36 can provide therapeutic benefit. A summary of these gaps in
knowledge is depicted in Figure 5.1. For the work completed in Chapter 4, the gaps in
knowledge that still remain to be addressed include i) which estrogen receptors contribute
to sex bias during skin infection, ii) whether targeting specific estrogen receptors has
therapeutic potential, and ii) whether estrogen is protective against other pathogens
causing skin disease. A summary of these gaps in knowledge is depicted in Figure 5.2.
The rationales behind these gaps and approaches to addressing them are discussed below.
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Figure 5.1 Multi-functional roles of CD36.
Future directions to investigate are enumerated. (1) Does upregulation of CD36 using
PPARγ agonists have therapeutic potential in treatment of S. aureus skin infection?
Expression of CD36 is regulated by binding of oxidized LDL or agonists for peroxisome
proliferating activated receptor (PPARγ), which acts as a transcription factor binding to
retinoid X receptor (RXR). (2) Will increased macrophage CD36 expression in CGD
patients provide protection against S. aureus SSTI by facilitating clearance of bacteria
and dying neutrophils? ROS is produced by the NADPH oxidase complex, which is
impaired in CGD patients. (3) Does soluble CD36 have a role in diabetic patient
susceptibility to infection by competitive binding to S. aureus ligands? Cellular CD36
functions as a co-receptor with TLR2 to recognize lipoteichoic acid or peptidoglycan
leading to phagocytosis of S. aureus. (4) Will therapeutic administration of peptides from
commensals (LP01) that signal through CD36 lead to upregulation of antimicrobial
peptides such as β–defensins and provide therapeutic benefit against S. aureus SSTI?
CD36 along with TLR2 recognizes LP01, produced by S. epidermidis, leading to
upregulation of antimicrobial peptides such as β–defensins.
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Figure 5.2 Role of estrogen in host defense.
Future directions to investigate are enumerated. (1) Which estrogen receptors (ERα, ERβ,
GPER) contribute to sex bias during skin infection? Estrogen leads to cell signaling
when it binds to any of the three estrogen receptors ERα, ERβ, and GPR30 (Kovats,
2015). Estrogen receptors ERα and ERβ (1a) can form heterodimers or homodimers
during ligand binding (Vrtacnik et al., 2014), which can then directly trigger gene
expression by binding to the Estrogen Response Element (ERE) found in the promoter of
various genes or by functioning as scaffolds for other transcription factors to bind
promoter regions of DNA and trigger gene expression. GPER (1b) is found in the
endoplasmic reticulum (Prossnitz et al., 2008), and estrogen binding leads to calcium
mobilization, activation of cAMP and signaling cascades through PI3K pathways
(Revankar et al., 2005). (2) Does targeting specific estrogen receptors with agonists or
antagonists have therapeutic potential? PPT and MPD are agonists and antagonists,
respectively for ERα. DPN and PHTPP are agonists and antagonists, respectively, of
ERβ. G1 and G36 are agonists and antagonists, respectively, of GPER. (3) Is estrogen
protective against other skin pathogens such as S. pyogenes?
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Part 1: Utilization of PPARγ agonists as therapeutics for S. aureus skin infections
The studies conducted in Chapter 3 suggest that, due to its multi-functional role in
combatting S. aureus skin infections, upregulation of CD36 on macrophages is a potential
therapeutic approach for protection against S. aureus skin infections. Due to its roles in
bacterial phagocytosis (Baranova et al., 2008; Stuart et al., 2005) and in regulation of the
innate immune response (Castleman et al., 2015), increased CD36 expression during skin
infection could enhance bacterial clearance and limit tissue damage caused by the host
response to virulence factors.

Expression of CD36 is regulated by binding of the

peroxisome proliferating activated receptor (PPARγ) transcription factor to the retinoid X
receptor (RXR), which subsequently binds the PPAR response element in the promoter
region of CD36 to activate gene expression (Hirano et al., 2003). PPARγ agonists have
commonly been used in biomedical research to increase the expression of CD36 on
various cells including macrophages in vitro and in vivo (Nicholson, 2004). For example,
PPARγ agonists are known to limit inflammation in the central nervous system and
attenuate microglial activation (Kielian and Drew, 2003).

For this reason, PPARγ

agonists have been used to treat S. aureus brain abscess development in mice by reducing
activation of microglial cells thereby reducing inflammation and enhancing bacterial
clearance (Kielian et al., 2008). However their utility in combatting the most common
form of S. aureus infection, in the skin, has not been addressed.
To find clinical evidence that PPARγ agonists are protective S. aureus skin
infections, we will use a national database to investigate the treatment of Type II
Diabetes mellitus patients with the PPARγ agonist, pioglitazone. Diabetic patients are
extremely susceptible to infection with S. aureus as it is present in up to 70% of diabetic
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infections in the U.S. (Eleftheriadou et al. 2010). Type II diabetic patients are prescribed
medications that increase insulin production by the pancreas, increase sensitivity of cells
to insulin or decrease glucose absorption in the gastrointestinal track all in order to lower
the levels of glucose in the blood (American Diabetes, 2009).

Drugs commonly

prescribed are in the classes of sensitizers (biguanides, thiazolidinediones), secretagogues
(sulfonylureas), and glucosidase inhibitors. Thiazolidinediones (TZDs), which function
to increase cell sensitivity to insulin, are agonists of PPARγ and one FDA approved drug
pioglitazone is currently prescribed to patients (Gillies and Dunn, 2000). We hypothesize
that diabetic patients treated with pioglitazone will display overall reduced incidence of
S. aureus skin infection compared to patients treated with other diabetic drugs. To
investigate this hypothesis we will obtain national estimates of drugs prescribed to
diabetic patients in order to determine the percent of patients taking pioglitazone
compared to other drugs. We will then query a national database containing diabetic
patient records of S. aureus skin infection. The data collected would need to be stratified
in order to eliminate comorbidities such as non-maintenance of diabetes or cardiovascular
disease. We will use this data to determine the incidence of diabetic patients that present
to the hospital with S. aureus skin infections and what drugs they are prescribed. If
diabetic patients who are prescribed drugs other than piolglitazone present more often
with a S. aureus skin infection, then that suggests that the PPARγ agonist piolglitazone is
protective against infection and provides evidence that investigation of PPARγ agonists
in combating S. aureus represents a viable research direction.
We hypothesize that using a PPARγ agonist to upregulate CD36 expression will
lead to increased clearance of apoptotic neutrophils. First we need to determine if
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increased CD36 expression on a CD36+/+ macrophage increases neutrophil clearance. A
preliminary assay to test this would be to overexpress CD36 in a macrophage cell line by
transfection of a plasmid containing the CD36 gene sequence or control plasmid. We
would verify increased CD36 expression using flow cytometry or western blot. We
would use a co-culture method to incubate macrophages with apoptotic neutrophils. We
expect that the cells overexpressing CD36 will be better able to clear the apoptotic
neutrophils compared to cells transfected with the control plasmid or CD36-/- cells. We
would follow this assay with another in vitro assay by treating macrophages with a
PPARγ agonist or vehicle control before incubation with apoptotic neutrophils. The
expected results for this assay are that the macrophages treated with the PPARγ agonist
will have increased CD36 expression and increased phagocytosis of neutrophils control
cells. These results would suggest that a PPARγ agonist could be protective in a murine
model of S. aureus skin infection through the known role of CD36 clearance of apoptotic
neutrophils (Castleman et al., 2015).
To test the hypothesis that a PPARγ agonist to upregulate CD36 expression will
be protective in a mouse model of S. aureus skin infection, we would infect mice
subcutaneously with S. aureus, then administer a PPARγ agonist therapeutically.
However with the long term goal of patient treatment in mind, careful considerations of
the utility of using PPARγ agonists as a treatment need to be taken into account. CD36
has mainly been studied for its contribution atherosclerosis (Park, 2014); it is a scavenger
receptor for oxLDL and uptake of too much oxLDL leads to foam cell formation, which
leads to development of atherosclerotic plaques (Febbraio et al., 2000). Despite CD36
having a demonstrated protective role against S. aureus infection, systemic enhancement
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of CD36 expression could be detrimental to the cardiovascular system. For this reason,
we propose that to modulate CD36 function against S. aureus skin infection, its
expression would need to be enhanced locally at the site of infection rather than
systemically to prevent undesirable side effects. Therefore, we recommend treatment
with a PPARγ agonist by injection near the site of infection or within a topical cream
formulated to trigger increased CD36 expression at the site of infection, to reduce or
prevent off target effects such as increased foam cell formation if treatment is given
systemically. In the S. aureus brain abscess study mentioned above (Kielian et al., 2008),
mice were treated intraperitoneal with 10 or 50 mg/kg/day of pioglitazone (FDA App.
No. NDA- 021073), an FDA approved PPAR agonist used to treat Type II Diabetes,
these concentrations limited inflammation without adverse effects such as extreme weight
loss and would serve as a guide for our initial studies. It would be clinically relevant to
determine if Type II diabetes patients prescribed pioglitazone present less often with S.
aureus skin infection. We would also need to investigate a dosing strategy for local or
topical administration of the PPARγ agonist to determine the following parameters;
optimal dose, frequency of dosing, and time until therapeutic effect is observed.

For

these studies, we expect that mice given the PPARγ agonist will show reduced
dermonecrosis and decreased inflammation in response to the S. aureus infection
compared to vehicle control treated mice, due to the functions of CD36 identified by
ourselves and others (Castleman et al., 2015; Savill et al., 1992; Stuart et al., 2005).
These expected results would indicate that PPARγ agonists may have clinical utility in
treatment against S. aureus skin infection via modulation of CD36 expression and
enhancement of the innate immune response.
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The increase in antibiotic resistant bacterial infections highlights the need for
therapeutic strategies that reduce the need for antibiotics or extend the life of current
antibiotics by reducing the dosage and frequency of use in the clinic. Should the use of
PPARγ agonists provide therapeutic protection against S. aureus skin infection, then we
propose an additional study to test the function of a PPARγ agonist as an adjunct to
antibiotics commonly used to treat MRSA skin infections (Stevens et al., 2014). We
hypothesize that therapeutic administration of a PPARγ agonist in conjunction with an
anti-staphylococcal antibiotic at suboptimal concentrations will be as protective in a
mouse model of S. aureus skin infection as treatment with antibiotic alone at standard
concentrations.

We expect that mice treated with the combination therapy will

demonstrate similarly reduced dermonecrosis and increased bacterial clearance as mice
given standard concentration monotherapy compared to no treatment. These results
would suggest that PPARγ agonists can enhance the lifetime of antibiotics currently in
use against S. aureus.
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Part 2: Utilization of PPARγ agonists as a therapeutic for chronic granulomatous
disease patients during S. aureus skin infections

Chronic granulomatous disease patients (CGD) are highly susceptible to S. aureus
skin infection. CGD is caused by genetic mutations in the genes coding for the subunits
of the NADPH oxidase, an enzymatic complex that generates ROS for oxidative killing
of bacterial pathogens and activation of antimicrobial proteins within the phagolysosome
(Holland, 2010; Segal et al., 2000). Patients with CGD are deficient in ROS production
and display exaggerated inflammation thought to result, at least in part, from
accumulation of apoptotic neutrophils (Fernandez-Boyanapalli et al., 2010).

Using

gp91phox-/- mice as a murine model of CGD, it was shown that these mice have reduced
expression of CD36 and have reduced clearance of apoptotic neutrophils, however
treatment with a PPARγ agonist reversed these phenotypes (Fernandez-Boyanapalli et al.,
2010). Furthermore, treatment of gp91phox-/- mice with a PPARγ agonist lead to enhanced
ROS production and significantly increased bacterial clearance compared to control
treated mice in a model of S. aureus peritonitis (Fernandez-Boyanapalli et al., 2015).
These studies suggest that upregulation of CD36 with a PPARγ agonist may provide
benefit to CGD patients against S. aureus skin infection since they are predisposed to
these infections. We hypothesize that gp91phox-/- mice treated with a PPARγ agonist
would have increased protection against S. aureus skin infection compared to untreated
mice. To test this we would infect gp91phox-/- mice subcutaneously with S. aureus, then
locally and therapeutically administer a PPARγ agonist. We expect that gp91phox-/- mice
given a PPARγ agonist would show reduced dermonecrosis, decreased inflammation and
increased bacterial clearance in response to the S. aureus infection compared to vehicle
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control treated mice, due to the increased expression of CD36. These expected results
would suggest that modulation of local CD36 expression via PPARγ agonists may have
clinical utility in treatment of S. aureus skin infections in CGD patients.
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Part 3: Examination of diabetic patients’ susceptibility to S. aureus infection

Diabetics are another patient population that is extremely susceptible to infection
with S. aureus. The prevalence of Type II Diabetes mellitus is increasing with 1.7
million new cases each year and currently it affects 9.3% of the U.S population
(American Diabetes, 2013). S. aureus is the most common pathogen affecting diabetic
patients as it is present in up to 70% of diabetic infections in the U.S. and almost half of
those are further attributed to infection with MRSA (Eleftheriadou et al. 2010). Patients
with diabetes may have an up to 4-fold increase in circulating CD36, found on
microvesicles in the blood, compared to non-diabetic controls (Alkhatatbeh et al., 2013).
High levels of circulating CD36 in the form of microvesicles, historically referred to as
soluble CD36 (sCD36) (Alkhatatbeh et al., 2011), is associated with increased risk of
Type II diabetes and insulin resistance (Handberg et al., 2010). However, whether
elevated levels of sCD36 impacts host innate defense against bacterial infection remains
to be investigated.
We hypothesize that sCD36 will antagonize host defense against S. aureus, unlike
its cellular form, because it lacks the ability to stimulate intracellular signaling to trigger
bacterial phagocytosis and clearance of apoptotic neutrophils. To first determine if
sCD36 recognizes and binds S. aureus, we would isolate microvesicles containing CD36
from the plasma of diabetic patients, incubate the microvesicles with a lipid intercalating
dye, then add them to an ELISA plate coated with S. aureus.

Binding of the

microvesicles to S. aureus could be quantified on a plate reader set to the appropriate
wavelength. We expect that sCD36 will still be able to bind S. aureus as it contains the
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same extracellular ligand binding sites as the cellular form. To determine if sCD36
antagonizes defense against S. aureus, we would isolate microvesicles containing sCD36
from the plasma of mice and incubate the microvesicles in increasing concentrations with
mouse macrophages and S. aureus. As a control, we would use microvesicles from
CD36-/- mice. We would measure phagocytosis of S. aureus and production of cytokines
by the macrophages. We expect that macrophages in the presence of increasing
concentrations of CD36+/+ microvesicles will phagocytose fewer bacteria compared to
controls and have reduced cytokine expression. These results would suggest that sCD36
is a non-functional scavenger for LTA and PGN from S. aureus, thereby competing for
binding (Stewart and Nagarajan, 2006), and preventing cellular CD36 from binding to the
appropriate ligands needed for initiation of host defense. These expected results could
provide some explanation for the enhanced susceptibility of diabetic patients to S. aureus
skin infection. These studies could then be repeated using microvesicles purified from the
plasma of diabetic patients.
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Part 4: Utilization of LP01 as a therapeutic for S. aureus skin infections
In addition to the roles described above, CD36 has indirect roles in host defense
against infection. For example, it was demonstrated that the commensal S. epidermis
secretes a lipopeptide called LP01, which activates TLR2 and CD36 on keratinocytes
leading to an increase in the production of antimicrobial peptides, including β-defensins
(hBD2 and hBD3) (Li et al., 2013). β-defensins have been shown to directly cause S.
aureus bacterial cell membrane lysis (Li et al., 2013; Ryu et al., 2014). Prophylactic
treatment of mice with 2mg/kg of LP01 before S. aureus SSTI, reduced bacterial burden
by increasing expression of mouse β-defensin 4 (Li et al., 2013). However, it is unknown
if administration of LP01 could be used therapeutically treat S. aureus skin infection. We
hypothesize that therapeutic administration of LP01 to S. aureus infected mice would aid
in combating infection.

We expect that mice given LP01 will produce more

antimicrobial peptides, have reduced dermonecrosis, and enhanced bacterial clearance in
response to skin infection.

These expected results would indicate that therapeutic

administration of LP01 enhances the natural defense mechanism of keratinocytes against
S. aureus and that products from other commensals or peptide mimetics could be utilized
to treat S. aureus skin infection. Furthermore, these results would suggest that previously
unknown ligands of CD36 may be useful in combating S. aureus skin infections via
enhancement of the host innate immune response, and that activation of CD36 with the
appropriate ligand could provide therapeutic benefit.
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Part 5: Investigation of intracellular signaling pathways important for CD36
protection against S. aureus skin infections

Macrophage identification of apoptotic neutrophils occurs through recognition of
“eat me” signals, such as expression of phosphatidylserine on the surface of the
neutrophils (Silva, 2011). This process is important to protection against tissue injury
caused by neutrophils undergoing a form of apoptosis called necrosis in which they
release toxic materials (Savill et al., 1989). Recognition of apoptotic neutrophils occurs
through the formation of a thrombospondin bridge, which binds both the macrophage and
neutrophil (Savill et al., 1992).

On the macrophage, CD36 is the receptor for

thrombospondin and works in conjunction with integrin αvβ3 to mediate clearance of
apoptotic neutrophils (Savill et al., 1992). The receptor for thrombospondin on the
apoptotic neutrophil has not yet been identified. Binding of the ligand oxLDL to CD36
leads to intracellular activation of Src family tyrosine kinases and serine/threonine
kinases resulting in actin polymerization (Silverstein and Febbraio, 2009), however the
intracellular pathways activated during thrombospondin binding have not been
investigated to our knowledge.
We hypothesize that binding of thrombospondin to CD36 leads to activation of
the Src family kinases which mediates actin polymerization for phagocytosis of apoptotic
neutrophils.

To investigate this we will use a co-culture method with healthy

macrophages along with neutrophils induced to an apoptotic state. We will treat the
macrophages with pharmacological Src family kinase inhibitor or vehicle control before
co-incubation with neutrophils.

We expect that the macrophages treated with the

inhibitor will have reduced neutrophil uptake and reduced actin polymerization. This
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assay will indicate that the macrophages treated with Src family kinases inhibitors will be
unable to signal intracellularly and that these kinases are important for macrophage
mediated of clearance of apoptotic neutrophils.
It is thought that the C-terminal domain of CD36 is integral for intracellular
signaling activation upon ligand binding, as single point mutations of specific tyrosine or
cytosine residues leads to CD36 unresponsiveness to ligand binding (Stuart et al., 2005).
However, the functional role of the intracellular C-terminal domain of CC36 in
intracellular signaling for clearance of apoptotic neutrophils has not been investigated.
To test that the C-terminal domain of CD36 is important for this process, we would
repeat the co-culture assay described above using macrophages that express CD36
containing point mutations in specific tyrosinse or cysteines in the C-terminal domain.
We expect that macrophages with mutations in CD36 will have reduced clearance of
apoptotic neutrophils. This data would suggest that the tyrosine or cytosine residues of
the C-terminus of CD36 are integral for intracellular signaling and phagocytosis.
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Part 6: Identification of the estrogen receptor(s) that mediate S. aureus clearance
during infection

The studies in Chapter 4 suggest that estrogen may be a viable therapeutic for the
treatment of S. aureus skin infection. Therefore it is important to determine which, or the
combination of which, of the estrogen receptors, ERα/ERβ/GPER, mediates this antibacterial immune response. To test the impact of each estrogen receptor on defense
against S. aureus we would compare the infection susceptibility of wild type versus
estrogen receptor mutant mice (αERKO, βERKO, and GPERKO). We hypothesize that
one or more of the estrogen receptor knockout mice will be more susceptible to S. aureus
skin infection because of the studies conducted in Chapter 4 indicating that estrogen
signaling is important for bacterial clearance.

Due to the complexity of estrogen

signaling during inflammation we expect that more than one murine knockout strain will
demonstrate increased dermonecrosis and bacterial burden in response to S. aureus skin
infection.

These expected results will identify which of the estrogen receptors are

important for intracellular signaling mechanisms to aid in bacterial clearance because in
their absence there is a reduction in bacterial clearance.
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Part 7: Utilization of estrogen receptor agonists as therapeutics for S. aureus skin
infections

We would use the knowledge gained from the studies above with the estrogen
receptor knockout mice to guide subsequent studies.

To determine if activation of

specific estrogen receptors identified above with synthetic agonists has therapeutic
potential against S. aureus skin infection, we would infect C57BL/6 mice subcutaneously
with S. aureus then, at various time points post-infection, treat with agonists for a specific
receptor, then measure disease outcome. In this study specific attention should be paid to
the method of agonist administration; it would be ideal to administer the agonist locally at
the site of infection via injection or cream formulation in order to prevent unnecessary off
target effects of other estrogen signaling pathways. Another important consideration for
these studies is that the estrogen receptors may trigger opposing signaling pathways. In
this instance, it may be necessary to combine an agonist of one receptor with an
antagonist of another receptor to trigger beneficial anti-bacterial signaling and prevent
conflicting signaling. We expect that mice treated with an agonist or combination of
agonists for the specific receptors will display reduced dermonecrosis, enhanced bacterial
clearance, and overall increased protection against S. aureus skin infection.

These

expected results will support a novel therapeutic strategy to bolster the innate immune
response against S. aureus skin infections.
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Part 8: Examination of intracellular signaling mechanism for estrogen protection
against S. aureus skin infections

Investigation of the signaling pathways triggered by the estrogen receptors that lead
to increased bacterial clearance is an important step in basic biomedical research. The
estrogen receptors ERα and ERβ form heterodimers or homodimers during ligand binding
(Vrtacnik et al., 2014). These receptor can directly trigger gene expression by binding to
the Estrogen Response Element (ERE) found in the promoter of various genes or by
functioning as scaffolds for other transcription factors to bind promoter regions of DNA
and trigger gene expression. To narrow the focus and identify specific genes activated for
host defense by the estrogen receptors we will use RNA sequencing on skin samples from
male and female mice infected with S. aureus and control uninfected mice to establish
baseline expression. We hypothesize that these estrogen response pathways trigger gene
expression important for increased production of reactive oxygen species or antimicrobial
peptides to kill phagocytosed bacteria. Genes that are upregulated or down regulated in
the female infected skin samples compared to the male samples could indicate a
contribution to host defense. These genes would be further investigated using both in
vitro and in vivo studies to verify their contribution to sex-bias in S. aureus infection.
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Part 9: Determination of the role of estrogen in innate host defense against other
bacterial skin infections

Although, S. aureus is the main contributor to skin infections, it is not the only
pathogen of clinical importance. Streptococcus pyogenes also contributes to the clinical
burden of infectious skin disease (Fiedler et al., 2015; Walker et al., 2014). Despite the
studies conducted in Chapter 4, in which a sex bias in susceptibility to S. aureus SSTI
was defined, it is still unknown if a sex bias exists in susceptibility to other skin infecting
pathogens such as S. pyogenes. We hypothesize that female mice will be resistant to
other skin disease causing bacterial pathogens because of the manner in which estrogen
enhances macrophage clearance of bacteria. To test this we would infect C57BL/6 male
and female mice subcutaneously with S. pyogenes and measure disease outcome. We
expect that female mice will demonstrate reduced dermonecrosis and increased bacterial
clearance compared to male mice. These expected results would indicate that estrogen
provides natural protection against skin disease caused by multiple pathogens.
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Conclusions
Despite significant scientific effort, no useful vaccine has shown clinical potential
against S. aureus infection. Furthermore, the ability of S. aureus to become resistant to
antibiotics highlights the need for the development of novel therapeutic approaches. The
long term goal of our studies investigating the host innate immune response to S. aureus
is to better understand how the host fights infection. At the same time, we hope to
identify approaches to promote host defense against infection. The relevance of the
studies we conducted in Chapter 3 to understanding how the host innate immune system
regulates the inflammatory response to infection is key to infection management. Any
therapeutics aimed at bacterial clearance need to avoid inducing an exacerbated
inflammatory response as it will damage surrounding tissue, while at the same time
supporting anti-inflammatory responses integral for wound resolution and tissue healing.
Our studies also underscore the importance of investigating receptors thought to have
fully defined functions for their contribution to host defense against pathogens. The
relevance of our studies in Chapter 4 to clinical treatment of S. aureus skin infections
cannot be overstated. The significance of the differing immune response between males
and females has long been overlooked and our data indicates that it may dictate the
effectiveness of clinical therapeutics. Future studies testing potential therapeutics against
S. aureus skin infections need to take into consideration the differing immune response
between males and females in order to determine the best method of treatment.
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Appendix A: List of Abbreviations
ADAM-10: a disintegrin and metalloprotease 10
AIP: auto-inducing peptide
Agr: accessory gene regulator
CA-MRSA: community acquired Methicillin-resistant Staphylococcus aureus
CD36: cluster of differentiation 36
ClfA: clumping factor A
DAMPS: danger-associated molecular patterns
E2: 17-β estradiol
ERα: estrogen receptor α
ERβ: estrogen receptor β
ERE: Estrogen Response Element
FnbpA: fibronectin-binding protein A
GPER: G-coupled protein estrogen receptor
GPR30: G-coupled protein receptor 30
hBD2: human β defensin 2
Hla: alpha hemolysin or alpha toxin
IsdA: iron surface determinant A
LPS: Lipopolysaccharide, or endotoxin
LTA: lipoteichoic acid
MPO: Myeloperoxidase
MSCRAMMS: microbial surface components recognizing adhesive matrix molecules
MSSA: Methicillin-susceptible Staphylococcus aureus
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MRSA: Methicillin-resistant Staphylococcus aureus
NETs: neutrophil extracellular traps
NLRP3: NLR family, pyrin domain containing 3
NOD2: nucleotide binding oligomerization domain containing protein 2
LIMP2: lysosomal integral membrane protein 2
oxLDL: oxidized low density lipoprotein
PAMPS: pathogen-associated molecular patterns
PPARγ: peroxisome proliferating activated receptor
PRR: pattern recognition receptors
ROS: reactive oxygen species
RXR: retinoid X receptor
SSSI: skin and skin structure infections
SSTI: skin and soft tissue infections
TLR2: Toll like receptor 2
WTA: wall teichoic acid
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